<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">Parkinsons Dis</journal-id><journal-id journal-id-type="publisher-id">PD</journal-id><journal-title-group><journal-title>Parkinson's Disease</journal-title></journal-title-group><issn pub-type="ppub">2090-8083</issn><issn pub-type="epub">2042-0080</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6906831</article-id><article-id pub-id-type="doi">10.1155/2019/4951379</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1809-8734</contrib-id><name><surname>Camargo Maluf</surname><given-names>Fauze</given-names></name><email>fauzecamargo@hotmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2366-5019</contrib-id><name><surname>Feder</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5485-7937</contrib-id><name><surname>Alves de Siqueira Carvalho</surname><given-names>Alzira</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Medical Student of Centro Universitario Saude ABC, Centro Universitario Saude ABC, FMABC, Santo Andre 09060-870, Brazil</aff><aff id="I2">
<sup>2</sup>Department of Pharmacology, Centro Universitario Saude ABC, FMABC, Santo Andre 09060-870, Brazil</aff><aff id="I3">
<sup>3</sup>Department of Neurosciences, Centro Universitario Saude ABC, FMABC, Santo Andre 09060-870, Brazil</aff><author-notes><fn fn-type="other"><p>Academic Editor: H&#x000e9;lio Teive</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>11</month><year>2019</year></pub-date><volume>2019</volume><elocation-id>4951379</elocation-id><history><date date-type="received"><day>1</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>1</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>6</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Fauze Camargo Maluf et al.</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>In the early sixties, a discussion started regarding the association between Parkinson's disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and &#x0201c;in vitro&#x0201d; models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1<italic>&#x003b1;</italic> (<italic>PGC-1&#x003b1;</italic>), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson's symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The prevalence of type 2 diabetes mellitus (T2DM) is 370 million people in the world. The T2DM is most frequent in adulthood; however, in the last years, the prevalence of T2DM is increasing in adolescents and children [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. T2DM is a chronic metabolic disease characterized by long-term insulin resistance and a decrease of <italic>&#x003b2;</italic>-cell function and population. These factors impair insulin release and consequently cause hyperglycemia [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. However, genetic and environmental factors are responsible for 20% of <italic>&#x003b2;</italic>-cell failure in the diabetic population [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>One of the consequences of chronic diabetes is the production of toxic aggregates of the islet amyloid polypeptide (IAPP). The IAPP might contribute to <italic>&#x003b2;</italic>-cell dysfunction [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Parkinson's disease (PD) affects about 1% of people over 65 and up to 4-5% of people over 85, and thus it represents the second most common neurodegenerative disorder [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>].</p><p>The diagnosis of PD is still based on the presence of symptoms and clinical signs such as typical asymmetric manifestation, the most common finding being tremor at rest in the upper limbs associated with bradykinesia, rigidity, and gait difficulty [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>The etiology of PD is based on the combination of genetic (10% of cases) and probably environmental factors [<xref rid="B9" ref-type="bibr">9</xref>]. Moreover, most of PD cases are idiopathic, and the exact etiology is still unclear [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>The concept of protein misfolding disorder (PMD) is relevant for the understanding of the potential association of T2DM and PD. Protein misfolding disorders (PMD) are diseases caused by a protein or peptide that has been misfolded, aggregated, and accumulated in certain tissues. There are at least 30 different PMDs, including neurodegenerative, systemic, and metabolic disorders such as PD and T2DM [<xref rid="B10" ref-type="bibr">10</xref>].</p><p>The specific protein that misfolds and could contribute to the pathogenesis of T2DM is called amylin. This protein is deposited as aggregates and has been found in the pancreas and brain tissue [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Human alpha-synuclein is the protein that misfolds and is thought by many to be related to the development of PD [<xref rid="B11" ref-type="bibr">11</xref>]. It is encoded by the alpha-synuclein gene (<italic>SNCA</italic>) and is expressed in neurological tissues and extraneurological tissues such as the pancreas [<xref rid="B11" ref-type="bibr">11</xref>]. The <italic>SNCA</italic> gene is associated with glucose and insulin regulation through K-channel modulation in <italic>&#x003b2;</italic> cells of the pancreas [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>] responsible for aggregation, toxicity, and Ca<sup>2+</sup> binding [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>In PD, there is the aggregation, deposition, and dysfunction of alpha-synuclein, which causes the accumulation and propagation of alpha-synuclein to various brain regions and cellular populations [<xref rid="B15" ref-type="bibr">15</xref>]. The levels of alpha-synuclein depend on the proportion between the synthesis, aggregation, and clearance of alpha-synuclein. A dysfunction in this proportion may result in high levels of alpha-synuclein that might favor the formation of toxic species [<xref rid="B16" ref-type="bibr">16</xref>]. Therefore, it is not unlikely that the two proteins, amylin and alpha-synuclein, would affect each other <italic>in vivo</italic>, causing T2DM and PD [<xref rid="B17" ref-type="bibr">17</xref>]. In addition, recent discoveries have showed common pathways that probably relate neurodegenerative mechanisms with abnormal glucose metabolism and abnormal mitochondrial function [<xref rid="B18" ref-type="bibr">18</xref>].</p><p>The association between T2DM and PD was previously reported since patients with T2DM seem to have an increased risk of also developing PD [<xref rid="B19" ref-type="bibr">19</xref>]. In a large cohort of 8 million people, Pablo-Fernandez et al., [<xref rid="B20" ref-type="bibr">20</xref>] showed a higher rate of subsequent PD following T2DM. However, there are studies that showed the opposite or no relation between these diseases [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>].</p><p>Another point suggesting a possible correlation between PD and T2DM has been demonstrated in the interaction of hypoglycemic and antiparkinsonian drugs. The recent studies took into account the effects of some drugs used to treat PD, such as levodopa, which induces both hyperglycemia and hyperinsulinemia [<xref rid="B23" ref-type="bibr">23</xref>], whereas others (including the ergot dopamine agonist bromocriptine) may increase insulin sensitivity [<xref rid="B24" ref-type="bibr">24</xref>]. In addition, hypoglycemic drugs such as biguanide [<xref rid="B25" ref-type="bibr">25</xref>], sulfonylureas [<xref rid="B26" ref-type="bibr">26</xref>], thiazolidinediones [<xref rid="B27" ref-type="bibr">27</xref>], and incretinomimetics [<xref rid="B28" ref-type="bibr">28</xref>] were used in the management of patients with PD.</p><p>T2DM and PD are common diseases that negatively affect patients' quality of life. Thus, it is of utmost importance not only to study these diseases in an isolated manner but also to investigate their correlations and interactions. So, this review aims to assess the risk factor association, the genetic link and the pathophysiologic interactions between T2DM and PD. Moreover, this review intends to determine the modifications on the clinical features when these diseases are associated and to evaluate the impact of hypoglycemic drugs on PD and antiparkinsonian drugs on T2DM.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><p>The review was based on the analysis of studies retrieved via PubMed up to September, 2019. Articles were screened according to the following eligibility criteria: original articles describing the relationship between PD and T2DM, unrelated to any other disease, using <italic>in vivo</italic> (human and animal) and <italic>in vitro</italic> models. The descriptors using the MeSH database were as follows: &#x0201c;(&#x0201c;Parkinson Disease&#x0201d;[Mesh]) AND &#x0201c;Diabetes Mellitus&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Parkinson Disease&#x0201d;[Mesh]) AND &#x0201c;Insulin Resistance&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;alpha-Synuclein&#x0201d;[Mesh]) AND &#x0201c;Diabetes Mellitus&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;alpha-Synuclein&#x0201d;[Mesh]) AND &#x0201c;Insulin Resistance&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Islet Amyloid Polypeptide&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Metformin&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Sulfonylurea Compounds&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Thiazolidinediones&#x0201d;[Mesh:NoExp]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Glucagon-Like Peptide 1&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Bromocriptine&#x0201d;[Mesh:NoExp]) AND &#x0201c;Diabetes Mellitus&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Exenatide&#x0201d;[Mesh:NoExp]) AND &#x0201c;Parkinsonian Disorders&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Levodopa&#x0201d;[Mesh]) AND &#x0201c;Diabetes Mellitus&#x0201d;[Mesh],&#x0201d; &#x0201c;(&#x0201c;Dipeptidyl-Peptidase IV Inhibitors&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh]&#x0201d;, &#x0201c;(&#x0201c;Sodium-Glucose Transporter 2 Inhibitors&#x0201d;[Mesh]) AND &#x0201c;Parkinson Disease&#x0201d;[Mesh].&#x0201d; Letters, reviews, and articles in languages other than English were excluded.</p></sec><sec id="sec3"><title>3. Results</title><p>A total of 627 articles were found (<xref rid="tab1" ref-type="table">Table 1</xref>). Among them, 96 were duplicated in searches with different descriptors, leaving 531 abstracts to be evaluated. Then, 157 articles were set aside to be fully read, from which 104 were used in the bibliography (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Our study showed connections between PD and T2DM in relation to epidemiology (<xref rid="tab2" ref-type="table">Table 2</xref>), genetics (<xref rid="tab3" ref-type="table">Table 3</xref>), clinical manifestations (<xref rid="tab4" ref-type="table">Table 4</xref>) and treatment (Tables <xref rid="tab5" ref-type="table">5</xref> and <xref rid="tab6" ref-type="table">6</xref>). We also found a relationship between both conditions in the pathophysiological mechanisms. In PD, mitochondrial dysfunction [<xref rid="B29" ref-type="bibr">29</xref>], mutations in different genes encoding alpha-synuclein, PINK-1 (PTEN-induced putative kinase 1), and DJ-1 (Protein deglycase) may favor the development of T2DM [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. Similarly, pathways of T2DM may influence the development of PD such as metabolic inflammation [<xref rid="B31" ref-type="bibr">31</xref>], downregulation of dopamine in the nigrostriatal pathway [<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>], long-term hyperglycemia [<xref rid="B35" ref-type="bibr">35</xref>], decrease in the expression of <italic>PGC-1&#x003b1;</italic> (peroxisome proliferator-activated receptor-gamma coactivator-1<italic>&#x003b1;</italic>) [<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>], increase in the expression of PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 protein) [<xref rid="B40" ref-type="bibr">40</xref>], increased methylglyoxal levels [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>], and the formation of alpha-synuclein amyloid fibrils [<xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec id="sec4"><title>4. Discussion</title><sec id="sec4.1"><title>4.1. Type 2 Diabetes vs. Parkinson's Disease: Epidemiology</title><p>The prevalence of T2DM patients suffering from PD is slightly heterogeneous, ranging between 3.4 and 9.1% [<xref rid="B123" ref-type="bibr">123</xref>], whereas in the general population the prevalence of PD is 1-2 per 1000 [<xref rid="B124" ref-type="bibr">124</xref>]. In this review, several studies suggested that T2DM might increase the risk of developing PD [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>]. This might possibly be explained due to the fact that both diseases share common pathophysiological pathways, such as increased iron levels [<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>] that may be involved in the insulin regulation in the nigrostriatal pathway [<xref rid="B32" ref-type="bibr">32</xref>] and low expression of <italic>PGC-1&#x003b1;</italic> gene that could lead to mitochondrial dysfunction [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. However, there are some studies that supported an inverse association [<xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>] or the lack of association [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>] between them. These conflicting findings could possibly be explained by factors like self-reported T2DM diagnosis [<xref rid="B55" ref-type="bibr">55</xref>] and study design (case-control studies) [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>] when the temporal relationship between disease onset and exposure is not clear. Additionally, a recent cohort with a sample size of approximately 8 million subjects indicated T2DM as a risk factor for PD [<xref rid="B20" ref-type="bibr">20</xref>]. This study excluded patients with cerebrovascular disease and drug-induced and vascular Parkinsonism which were not considered in previous studies [<xref rid="B20" ref-type="bibr">20</xref>].</p><p>As for the inverse association, PD patients less frequently suffer from T2DM owing to the decrease in sympathetic activity caused by PD [<xref rid="B59" ref-type="bibr">59</xref>] and the use of L-dopa, a drug that increases glycogenolysis and inhibits the use of peripheral glucose [<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B127" ref-type="bibr">127</xref>]. Only one study showed a higher chance for the development of T2DM in PD patients [<xref rid="B60" ref-type="bibr">60</xref>]. A possible explanation for this is the abnormal tolerance to glucose in approximately half of the patients with PD [<xref rid="B128" ref-type="bibr">128</xref>] that could evolve to T2DM.</p><p>Many factors related to lifestyle and genetics are interconnected with the risks of T2DM and PD. Advanced age is the main risk factor for developing PD [<xref rid="B129" ref-type="bibr">129</xref>] and an important factor for the onset of T2DM [<xref rid="B130" ref-type="bibr">130</xref>]. Interestingly, it was observed that smoking increased the risk of T2DM and reduced the risk of PD [<xref rid="B131" ref-type="bibr">131</xref>].</p></sec><sec id="sec4.2"><title>4.2. Type 2 Diabetes vs. Parkinson's Disease: Genetics</title><p>PD and T2DM are complex, multifactorial disorders with a combination of environmental and genetic factors involved in the pathogenesis of the diseases. PD and T2DM with genetic alterations represent 5&#x02013;10% of cases [<xref rid="B132" ref-type="bibr">132</xref>].</p><p>The genetic relationship between these diseases was confirmed by genetic mapping of the genes in both diseases. In this study, a genome-wide association study (GWAS) and microarrays showed 478 genes closely associated with confirmed PD and T2DM [<xref rid="B63" ref-type="bibr">63</xref>]. In a different study, using only GWAS, 84 PD, and T2DM-associated genes were identified [<xref rid="B62" ref-type="bibr">62</xref>]. Therefore, it is believed that genes associated with T2DM can be used to identify PD genes, and the PD genes can identify T2DM genes, as well [<xref rid="B63" ref-type="bibr">63</xref>]. However, in another study, the GWAS analysis of PD and T2DM did not reveal any significant relationship between the diseases [<xref rid="B61" ref-type="bibr">61</xref>]. This fact could be explained because the authors exclusively analyzed the top candidate variants which precluded to find rare genetic variants or copy-number variations [<xref rid="B61" ref-type="bibr">61</xref>].</p><p>Moreover, T2DM and PD patients have a common haplogroup, B5b [<xref rid="B64" ref-type="bibr">64</xref>], indicating that they share same genetic mutations in mitochondrial DNA (mtDNA), such as the presence of the adenine in position 709 of the mtDNA (709G&#x0003e;A). The mitochondrial dysfunction present in both pathologies could therefore be explained by this finding [<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B133" ref-type="bibr">133</xref>].</p><p>Finally, in microarray analyses, seven deregulated genes, the amyloid precursor protein (<italic>APP</italic>) gene in particular, were quantified by gene expression from blood samples of T2DM and PD patients [<xref rid="B63" ref-type="bibr">63</xref>]. Actually, the expression of <italic>APP</italic> is increased in PD and prediabetic patients [<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>], suggesting that high levels of the protein encoded by this gene in the blood of T2DM patients could be an indicator of neurodegeneration [<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B136" ref-type="bibr">136</xref>].</p></sec><sec id="sec4.3"><title>4.3. Type 2 Diabetes vs. Parkinson's Disease: Clinical Manifestations</title><p>Patients with both T2DM and PD have a noticeable aggravation of motor symptoms, higher degree of cognitive impairment and earlier onset of complications [<xref rid="B65" ref-type="bibr">65</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B71" ref-type="bibr">71</xref>]. Regarding motor symptoms, the worsening was especially observed in the postural instability and mobility of these patients [<xref rid="B69" ref-type="bibr">69</xref>&#x02013;<xref rid="B71" ref-type="bibr">71</xref>], whereas attention impairment and slower speed of thinking were noted in the cognitive processes [<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B67" ref-type="bibr">67</xref>]. Such damages may be associated with dopamine regulation deficiency and neuroinflammation [<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>], confirmed by image tests that showed white matter injuries, lacunar infarctions and cortical atrophy in T2DM patients [<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B138" ref-type="bibr">138</xref>]. Moreover, motor complications (motor fluctuations and dyskinesia) happened one year earlier compared with subjects with only PD [<xref rid="B68" ref-type="bibr">68</xref>]. Therefore, longer periods of hospitalization, as well as daily care, are typically required for these patients [<xref rid="B72" ref-type="bibr">72</xref>].</p><p>In addition, the risk of cerebrovascular accident (CVA) in patients with T2DM and PD is higher than in those with T2DM only [<xref rid="B72" ref-type="bibr">72</xref>]. A possible reason for this higher incidence is the fact that PD patients have increased levels of homocysteine due to the use of L-dopa increasing the synthesis of free radicals and enhancing neuroinflammation [<xref rid="B139" ref-type="bibr">139</xref>].</p><p>Patients with PD and T2DM showed a reduction in HbA1c and an improvement in the lipid profile [<xref rid="B72" ref-type="bibr">72</xref>]. The use of drugs for the treatment of PD, bromocriptine in particular, as well as the reduction in the sympathetic activity and hypothalamic-pituitary-adrenal axis impairment [<xref rid="B59" ref-type="bibr">59</xref>] would probably decrease the production of catecholamines and cortisol resulting in lower levels of glycemia [<xref rid="B59" ref-type="bibr">59</xref>]. Concerning the improvement in the lipid profile, no relevant hypothesis has yet been made. One possible explanation is the fact that dyskinesia and decreased physical activity observed in some PD patients may lead to less food intake, which could reduce the lipid level [<xref rid="B140" ref-type="bibr">140</xref>]. However, more studies are necessary to explore the potential pathophysiology of better levels of lipid in PD and T2DM patients.</p></sec><sec id="sec4.4"><title>4.4. Type 2 Diabetes vs. Parkinson's Disease: Pathophysiology</title><p>Based on results of &#x0201c;in vitro&#x0201d; studies and studies using animal models, this review suggests that there are common pathophysiological features involving T2DM and PD (Figures <xref ref-type="fig" rid="fig2">2</xref> and <xref ref-type="fig" rid="fig3">3</xref>).</p><p>Many studies suggested pathophysiological mechanisms already related to PD that may favor the development of T2DM such as mitochondrial dysfunction [<xref rid="B29" ref-type="bibr">29</xref>], mutations in genes encoding alpha-synuclein, PINK-1 (PTEN-induced putative kinase 1), and DJ-1 (Protein deglycase) [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B30" ref-type="bibr">30</xref>].</p><p>The neuroinflammatory processes observed in PD activate microglia cells, causing the overproduction of reactive oxygen species (ROS) and proinflammatory cytokines (nitrous oxide and tumor necrosis factor-alpha) with resulting mitochondrial dysfunction [<xref rid="B141" ref-type="bibr">141</xref>].</p><p>To simulate the mitochondrial dysfunction in PD, many studies used the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This drug mimics PD-like symptoms and inhibits complex I of the respiratory chain [<xref rid="B142" ref-type="bibr">142</xref>&#x02013;<xref rid="B144" ref-type="bibr">144</xref>] by decreasing ATP production and triggering the release of free radicals, thus leading to the death of dopaminergic neurons [<xref rid="B29" ref-type="bibr">29</xref>]. The mitochondrial dysfunction caused by PD may accelerate the progression of insulin resistance via increased production of ROS [<xref rid="B145" ref-type="bibr">145</xref>]. Therefore, it is possible that the mitochondrial dysfunction observed in PD could promote the development of T2DM.</p><p>In relation to mutations in gene-encoding proteins, studies using alpha-synuclein in rats showed that this protein lowers the resistance to insulin [<xref rid="B12" ref-type="bibr">12</xref>]. In PD, the mutated alpha-synuclein could trigger the formation of aggregates of the protein [<xref rid="B146" ref-type="bibr">146</xref>], thus impairing insulin resistance and increasing the likelihood of developing T2DM [<xref rid="B147" ref-type="bibr">147</xref>].</p><p>Moreover, the deficiency of DJ-1 inhibits the aggregation of alpha-synuclein and increases the resistance to insulin in rats [<xref rid="B148" ref-type="bibr">148</xref>]. Likewise, PINK-1 deficiency, present in PD, also favors resistance to insulin [<xref rid="B30" ref-type="bibr">30</xref>]. Hence, mutations of alpha-synuclein, DJ-1, and PINK-1 are important related factors that may favor the development of T2DM in PD patients.</p><p>On the other hand, we also found pathophysiological components of T2DM that could lead to PD such as metabolic inflammation [<xref rid="B31" ref-type="bibr">31</xref>], downregulation of dopamine in the nigrostriatal pathway [<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>], long-term hyperglycemia condition [<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29890391">35</ext-link>], decrease in the expression of <italic>PGC-1&#x003b1;</italic> (peroxisome proliferator-activated receptor-gamma coactivator-1<italic>&#x003b1;</italic>) [<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>], increase in the expression of PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 protein) [<xref rid="B40" ref-type="bibr">40</xref>], increased methylglyoxal levels [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>], and the formation of alpha-synuclein amyloid fibrils [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Many studies evaluated the use of MPTP in diabetic rats to analyze the pathophysiological interaction between both diseases. The use of MPTP in diabetic rats resulted not only an accelerated loss of dopaminergic neurons and the activation of glial cells in the substantia nigra but also an increase in the activation of inflammatory molecules, including NLRP3 and alpha-synuclein aggregates in the pancreas and in the brain. In addition, the endoplasmic reticulum stress markers CHOP and GRP78 were positively regulated in the pancreas, liver, and brain of mice with T2DM [<xref rid="B31" ref-type="bibr">31</xref>]. Therefore, the metabolic inflammation in T2DM may contribute to the occurrence of PD.</p><p>Futhermore, it was observed that insulin regulates dopamine synthesis and uptake within the substantia nigra [<xref rid="B34" ref-type="bibr">34</xref>]. Some studies have revealed that the impaired insulin signaling in T2DM causes the degeneration of the nigrostriatal dopaminergic pathway and an exacerbated neurodegeneration in animals [<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>] that consequently could facilitate the onset of PD-like symptoms. In addition, long-term hyperglycemia in a rat model also caused nigrostriatal dopaminergic neurodegeneration due to elevated basal oxidative burden and motor impairments that are similar to early parkinsonian symptomatology [<xref rid="B35" ref-type="bibr">35</xref>].</p><p>In insulin resistance, the gene <italic>PGC-1&#x003b1;</italic>, a regulator of enzymes involved in mitochondrial respiration, shows reduced expression [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B39" ref-type="bibr">39</xref>]. Additionally, <italic>PGC-1&#x003b1;</italic> is repressed by PARIS (ZNF746), a protein that causes neurodegeneration in PD due to parkin inactivation [<xref rid="B37" ref-type="bibr">37</xref>]. Many researchers observed that <italic>PGC-1&#x003b1;</italic> protects against the destruction of dopaminergic neurons [<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>]. As a consequence, the decreased protection of these neurons in T2DM may lead to the development of PD.</p><p>Another pathophysiological mechanism in T2DM is the protein PED/PEA-15. This protein is increased in many cells (skeletal muscles, adipocytes, skin fibroblasts, and peripheral blood leukocytes) in T2DM patients. A recent study showed that rats overexpressing this protein had a reduction in dopaminergic activity, a fact that may induce the development of PD [<xref rid="B40" ref-type="bibr">40</xref>].</p><p>One recent association between PD and T2DM is the ADTIQ (1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) and its precursor methylglyoxal (a subproduct of glucose metabolism that is increased in diabetic patients) [<xref rid="B149" ref-type="bibr">149</xref>]. ADTIQ was recently discovered in frozen human PD brain tissues [<xref rid="B150" ref-type="bibr">150</xref>], and its role could be as an endogenous neurotoxin that causes PD [<xref rid="B151" ref-type="bibr">151</xref>]. In diabetic rats, it was observed that the accumulation of ADTIQ, produced by the reaction of dopamine and methylglyoxal, caused neuronal injury, oxidative stress, and apoptosis [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>]. Therefore, it is possible that ADTIQ may be an important factor to increase the risk of PD in patients with T2DM.</p><p>Finally, the formation of alpha-synuclein aggregates can be observed in PD, whereas pancreatic amyloid plaques formed by the pancreatic islet amyloid polypeptide (IAPP) are present in T2DM. In one study, it was noted that the speed of alpha-synuclein aggregation is higher when it interacts with IAPP [<xref rid="B17" ref-type="bibr">17</xref>], thus showing an increased propensity for the development of PD in T2DM cases. A possible explanation could be the excessive glycation process in T2DM patients. In this process, proteins undergo posttranslational modification, which affects the alpha-synuclein structure and increases its aggregation [<xref rid="B152" ref-type="bibr">152</xref>].</p></sec><sec id="sec4.5"><title>4.5. Type 2 Diabetes vs. Parkinson's Disease: Treatment Related Issues</title><sec id="sec4.5.1"><title>4.5.1. Antidiabetic Drugs</title><p>Biguanides (metformin) activate the AMP-activated kinase protein (AMPK) [<xref rid="B153" ref-type="bibr">153</xref>] responsible for the homeostatic control of cellular energy balance, glucose absorption in the muscle, and the inhibition of hepatic glucose production [<xref rid="B154" ref-type="bibr">154</xref>]. In rodent models, these properties neutralize the toxicity of MPTP through the reduction of oxidative stress levels [<xref rid="B155" ref-type="bibr">155</xref>], the neurogenic potential of this drug [<xref rid="B156" ref-type="bibr">156</xref>], and the restoration of the mitochondrial membrane potential [<xref rid="B89" ref-type="bibr">89</xref>]. Metformin also was associated with neuroprotection by ameriolating the neurotoxicity of alpha-synuclein in human neuroblastoma SH-SY5Y cells [<xref rid="B157" ref-type="bibr">157</xref>]. Futhermore, two studies observed the neuroprotection of metformin through the improvement in the motor function of the animals [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. Nevertheless, one study showed an increased risk of PD associated with the use of metformin in a mouse model [<xref rid="B85" ref-type="bibr">85</xref>]. In human trials, metformin was usually combined with other antidiabetic drugs such as sulphonylureas [<xref rid="B47" ref-type="bibr">47</xref>] and thiazolidinediones [<xref rid="B117" ref-type="bibr">117</xref>]. Only one trial studied metformin individually and found a higher incidence of PD [<xref rid="B88" ref-type="bibr">88</xref>]. The increased risk of PD could be explained by the elevation of AMP/ATP and ADP/ATP ratios that occurs through the activation of AMPK, with inhibition of the mitochondrial complex I and, as a result, an increase in vulnerability as well as degeneration of dopaminergic neurons [<xref rid="B85" ref-type="bibr">85</xref>]. The effect of metformin in patients with PD has not been fully elucidated. Therefore, the potential benefit or harm of metformin in patients with PD remains to be determined.</p><p>Sulphonylureas (glibenclamide, tolbutamine, and glipizide) stimulate insulin release by inhibiting the ATP-sensitive K+ (K ATP) channel of pancreatic beta-cells resulting in the closure of the potassium channels and opening of calcium channels [<xref rid="B158" ref-type="bibr">158</xref>]. However, these channels are present not only in the pancreas but also in cardiac, skeletal cells, and in neurons of the central nervous system (cortex, basal ganglia, hippocampus, hypothalamus, and striated muscles in particular) [<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>]. The activation of K ATP channels in the central nervous system has already been associated as a protector of mitochondria function [<xref rid="B161" ref-type="bibr">161</xref>]. Consequently, it is possible that the inhibition of K ATP channels might intensify mitochondria dysfunction and aggravates the neurological complications in PD patients [<xref rid="B108" ref-type="bibr">108</xref>]. Sulphonylureas did not show neuroprotection in any of the analyzed studies [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B108" ref-type="bibr">108</xref>], which could be a predisposing factor for the development of PD.</p><p>Several studies investigated the effect of thiazolidinediones (pioglitazone and rosiglitazone) in the treatment of PD [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B109" ref-type="bibr">109</xref>&#x02013;<xref rid="B122" ref-type="bibr">122</xref>]. They act on peroxisome proliferator-activated receptor-gamma (PPAR-y) receptors by boosting the action of insulin [<xref rid="B162" ref-type="bibr">162</xref>] and bind to the protein of the external mitochondrial membrane [<xref rid="B163" ref-type="bibr">163</xref>&#x02013;<xref rid="B165" ref-type="bibr">165</xref>]. This interaction showed positive effects on the activity of complex I of the respiratory chain in neuronal cells, which can reverse mitochondrial dysfunction in PD [<xref rid="B166" ref-type="bibr">166</xref>]. Besides, these drugs showed a protective action against neurodegeneration and neuroinflammation in MPTP-treated rodents, triggered by either a lipopolysaccharide model or an L-dopa-induced dyskinesia model, as well as in humans [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B109" ref-type="bibr">109</xref>&#x02013;<xref rid="B122" ref-type="bibr">122</xref>]. This protective property of thiazolidinediones can be explained by the activation of PPAR-y, which reduced or reversed the microglial polarity, resulting in a decrease in nitric oxide synthase (NOS) activity, oxidative stress, and free radical release [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>]. Some studies, however, suggested the beneficial action of thiazolidinediones through the inhibition of monoamine oxidase B (MAO-B) preventing the breakdown of dopamine and, consequently, increasing the levels of dopamine [<xref rid="B113" ref-type="bibr">113</xref>]. Surprisingly, a recent 44-week placebo-controlled phase 2 study in 210 PD patients did not show the neuroprotective effect of this drug [<xref rid="B119" ref-type="bibr">119</xref>]. In addition, a different study could not identify a reduction in the biomarkers of PD in patients on pioglitazone, such as leukocyte <italic>PGC-1&#x003b1;</italic>, plasma interleukin 6, and urine 8-hydroxydeoxyguanosine [<xref rid="B120" ref-type="bibr">120</xref>]. However, it is important to underline that these biomarkers are not FDA approved. Therefore, according to these new studies, there appears to be no potential for this drug to treat PD neurodegeneration.</p><p>Incretin mimetics drugs (GLP-1/GIP agonists and DPP-4 inhibitors) activate glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptors on pancreatic beta-cells stimulating insulin secretion and synthesis [<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B166" ref-type="bibr">166</xref>]. The activation of the GLP-1 receptor by GLP-1 agonists (exenatide, liraglutide, and semaglutide) seems to prevent the death of dopaminergic neurons and improve motor and cognitive functions [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B90" ref-type="bibr">90</xref>&#x02013;<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B99" ref-type="bibr">99</xref>&#x02013;<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>]. These facts can be explained by the increase in levels of tyrosine hydroxylase and vesicular monoamine transporter 2 (VMAT-2) in neurons of the nigrostriatal system along with the inhibition of microglial activation and the release of proinflammatory mediators [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B95" ref-type="bibr">95</xref>&#x02013;<xref rid="B97" ref-type="bibr">97</xref>]. A recent study suggested the possible neuroprotective effect of exenatide through the activation of protein kinase B (PKB) and the mitogen-activated protein kinase (MAP kinase) pathways. Together, they influence not only neuroinflammation but also neuronal and mitochondrial survival pathways [<xref rid="B169" ref-type="bibr">169</xref>]. Besides, a groundbreaking randomised, double-blind, placebo-controlled trial demonstrated that PD patients treated with exenatide once in a week for 48 weeks had a 3.5-point advantage over placebo in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [<xref rid="B97" ref-type="bibr">97</xref>]. In fact, this is the first time that a disease-modifying drug for the diabetes treatment had a relevant positive effect on PD progression [<xref rid="B170" ref-type="bibr">170</xref>]. Moreover, another study reported that the neuroprotection offered by exenatide persisted after 12 months of treatment in 20 patients with PD [<xref rid="B98" ref-type="bibr">98</xref>], thus providing positive evidence for the potential of GLP-1 agonists. Regarding GIP agonists (D-Ala2-GIP-glu-PAL), neuroprotection in MPTP-treated rats and cell cultures was confirmed through the reduction in dopaminergic neurons and an increase in the antiapoptotic protein Bcl-2 (<italic>&#x003b2;</italic>-cell lymphoma 2), which prevented apoptosis and reduced chronic brain inflammation [<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>]. Finally, DPP-4 inhibitors slow degradation of GLP-1 increasing the insulin secretion [<xref rid="B171" ref-type="bibr">171</xref>]. This drug has demonstrated antiparkinsonian effects [<xref rid="B104" ref-type="bibr">104</xref>&#x02013;<xref rid="B106" ref-type="bibr">106</xref>] explained by the reduction in ROS expression, brain mitochondrial dysfunction in diabetic rats [<xref rid="B104" ref-type="bibr">104</xref>], and the suppression of neuroinflammatory and apoptotic cascades in models of PD induction in rats [<xref rid="B105" ref-type="bibr">105</xref>]. Moreover, a nationwide case-control study showed, for the first time, a decreased risk of future PD in patients using DPP-4 inhibitors [<xref rid="B106" ref-type="bibr">106</xref>]. However, the whole mechanism of action of DPP-4 against neurodegeneration in PD is not fully understood [<xref rid="B172" ref-type="bibr">172</xref>]. Hence, further studies on the neuroprotective potential of incretin mimetics for the treatment of PD should be conducted.</p></sec><sec id="sec4.5.2"><title>4.5.2. Antiparkinsonian Drugs</title><p>A relationship between T2DM and L-dopa therapy [<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B73" ref-type="bibr">73</xref>] and dopaminergic agonists, especially bromocriptine [<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B80" ref-type="bibr">80</xref>&#x02013;<xref rid="B83" ref-type="bibr">83</xref>], has been detected. In trials with rodents, L-dopa therapy caused a decrease in insulin secretion in glucose tolerance tests due to the dopamine increase in pancreatic cells [<xref rid="B173" ref-type="bibr">173</xref>]. In addition, a partial loss of L-dopa efficacy in PD patients who developed T2DM [<xref rid="B71" ref-type="bibr">71</xref>] was observed probably because some pathophysiological mechanisms of T2DM can aggravate PD. Bromocriptine has an inhibitory effect on the production and release of prolactin, preventing disorders of carbohydrate and lipid metabolism due to the excessive amount of this hormone. In animals and patients with T2DM, there is an improvement in glucose intolerance [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B175" ref-type="bibr">175</xref>], a reduction in the production of hepatic glucose, in serum lipid levels [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B83" ref-type="bibr">83</xref>] and in the risk of cardiovascular complications [<xref rid="B77" ref-type="bibr">77</xref>].</p></sec></sec></sec><sec id="sec5"><title>5. Conclusion</title><p>&#x0201c;In vitro&#x0201d; and animal studies suggest that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1<italic>&#x003b1;</italic> (<italic>PGC-1&#x003b1;</italic>), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. Epidemiological studies suggested that T2DM increases the risks of PD. In addition, clinical studies described that Parkinson's symptoms were notably worse after the onset of T2DM. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer a certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.</p></sec></body><back><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinhas-Hamiel</surname><given-names>O.</given-names></name><name><surname>Zeitler</surname><given-names>P.</given-names></name></person-group><article-title>The global spread of type 2 diabetes mellitus in children and adolescents</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>2005</year><volume>146</volume><issue>5</issue><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.12.042</pub-id><pub-id pub-id-type="other">2-s2.0-18144382988</pub-id><pub-id pub-id-type="pmid">15870677</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>S. E.</given-names></name><name><surname>Cooper</surname><given-names>M. E.</given-names></name><name><surname>Del Prato</surname><given-names>S.</given-names></name></person-group><article-title>Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2014</year><volume>383</volume><issue>9922</issue><fpage>1068</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(13)62154-6</pub-id><pub-id pub-id-type="other">2-s2.0-84896495719</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaccardi</surname><given-names>F.</given-names></name><name><surname>Webb</surname><given-names>D. R.</given-names></name><name><surname>Yates</surname><given-names>T.</given-names></name><name><surname>Davies</surname><given-names>M. J.</given-names></name></person-group><article-title>Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective</article-title><source><italic toggle="yes">Postgraduate Medical Journal</italic></source><year>2015</year><volume>92</volume><issue>1084</issue><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1136/postgradmedj-2015-133281</pub-id><pub-id pub-id-type="other">2-s2.0-84955749058</pub-id><pub-id pub-id-type="pmid">26621825</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>S.</given-names></name><name><surname>Dey</surname><given-names>D.</given-names></name><name><surname>Roy</surname><given-names>S. S.</given-names></name></person-group><article-title>Molecular mechanism of insulin resistance</article-title><source><italic toggle="yes">Journal of Biosciences</italic></source><year>2007</year><volume>32</volume><issue>2</issue><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1007/s12038-007-0038-8</pub-id><pub-id pub-id-type="other">2-s2.0-34247383057</pub-id><pub-id pub-id-type="pmid">17435330</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obasse</surname><given-names>I.</given-names></name><name><surname>Taylor</surname><given-names>M.</given-names></name><name><surname>Fullwood</surname><given-names>N. J.</given-names></name><name><surname>Allsop</surname><given-names>D.</given-names></name></person-group><article-title>Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes</article-title><source><italic toggle="yes">Interface Focus</italic></source><year>2017</year><volume>7</volume><issue>6</issue><pub-id pub-id-type="publisher-id">20160127</pub-id><pub-id pub-id-type="doi">10.1098/rsfs.2016.0127</pub-id><pub-id pub-id-type="other">2-s2.0-85032010038</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>M.</given-names></name><name><surname>Targa</surname><given-names>A.</given-names></name><name><surname>Noseda</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Does Parkinson&#x02019;s disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?</article-title><source><italic toggle="yes">CNS &#x00026; Neurological Disorders-Drug Targets</italic></source><year>2014</year><volume>13</volume><issue>3</issue><fpage>418</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.2174/18715273113126660155</pub-id><pub-id pub-id-type="other">2-s2.0-84904463268</pub-id><pub-id pub-id-type="pmid">24059307</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mhyre</surname><given-names>T. R.</given-names></name><name><surname>Boyd</surname><given-names>J. T.</given-names></name><name><surname>Hamill</surname><given-names>R. W.</given-names></name><name><surname>Maguire-Zeiss</surname><given-names>K. A.</given-names></name></person-group><article-title>Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease</italic></source><year>2012</year><volume>65</volume><fpage>389</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-5416-4_16</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>H. H.</given-names></name></person-group><article-title>2015 Update on Parkinson disease</article-title><source><italic toggle="yes">Cleveland Clinic Journal of Medicine</italic></source><year>2015</year><volume>82</volume><issue>9</issue><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.3949/ccjm.82gr.15004</pub-id><pub-id pub-id-type="other">2-s2.0-84983168941</pub-id><pub-id pub-id-type="pmid">26366951</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>B.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group><article-title>Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Human Molecular Genetics</italic></source><year>2007</year><volume>16</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm159</pub-id><pub-id pub-id-type="other">2-s2.0-37349004102</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanis</surname><given-names>L.</given-names></name></person-group><article-title>-Synuclein in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Cold Spring Harbor Perspectives in Medicine</italic></source><year>2011</year><volume>2</volume><issue>2</issue><pub-id pub-id-type="publisher-id">a009399</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a009399</pub-id><pub-id pub-id-type="other">2-s2.0-84866702836</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emamzadeh</surname><given-names>F.</given-names></name></person-group><article-title>Alpha-synuclein structure, functions, and interactions</article-title><source><italic toggle="yes">Journal of Research in Medical Sciences</italic></source><year>2016</year><volume>21</volume><issue>1</issue><fpage>p. 29</fpage><pub-id pub-id-type="doi">10.4103/1735-1995.181989</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Araujo</surname><given-names>G.</given-names></name><name><surname>Nakagami</surname><given-names>H.</given-names></name><name><surname>Takami</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Low alpha-synuclein levels in the blood are associated with insulin resistance</article-title><source><italic toggle="yes">Science Reports</italic></source><year>2015</year><volume>5</volume><issue>1</issue><fpage>p. 12081</fpage><pub-id pub-id-type="doi">10.1038/srep12081</pub-id><pub-id pub-id-type="other">2-s2.0-84937019580</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shendure</surname><given-names>J.</given-names></name><name><surname>Church</surname><given-names>G. M.</given-names></name></person-group><article-title>Computational discovery of sense-antisense transcription in the human and mouse genomes</article-title><source><italic toggle="yes">Genome Biology</italic></source><year>2002</year><volume>3</volume><issue>9</issue><pub-id pub-id-type="publisher-id">research0044.1</pub-id><pub-id pub-id-type="doi">10.1186/gb-2002-3-9-research0044</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name></person-group><article-title>Alpha-synuclein in Parkinson&#x02019;s disease: from pathogenetic dysfunction to potential clinical application</article-title><source><italic toggle="yes">Parkinson&#x02019;s Disease</italic></source><year>2016</year><volume>2016</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2016/1720621</pub-id><pub-id pub-id-type="other">2-s2.0-84984706735</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamg&#x000fc;ney</surname><given-names>G.</given-names></name><name><surname>Korczyn</surname><given-names>A. D.</given-names></name></person-group><article-title>A critical review of the prion hypothesis of human synucleinopathies</article-title><source><italic toggle="yes">Cell and Tissue Research</italic></source><year>2018</year><volume>373</volume><issue>1</issue><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00441-017-2712-y</pub-id><pub-id pub-id-type="other">2-s2.0-85033411506</pub-id><pub-id pub-id-type="pmid">29116402</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oueslati</surname><given-names>A.</given-names></name><name><surname>Ximerakis</surname><given-names>M.</given-names></name><name><surname>Vekrellis</surname><given-names>K.</given-names></name></person-group><article-title>Protein transmission, seeding and degradation: key steps for <italic>&#x003b1;</italic>-synuclein prion-like propagation</article-title><source><italic toggle="yes">Experimental Neurobiology</italic></source><year>2014</year><volume>23</volume><issue>4</issue><fpage>p. 324</fpage><pub-id pub-id-type="doi">10.5607/en.2014.23.4.324</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>I.</given-names></name><name><surname>Wittung-Stafshede</surname><given-names>P.</given-names></name></person-group><article-title>Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2016</year><volume>113</volume><issue>44</issue><fpage>12473</fpage><lpage>12477</lpage><pub-id pub-id-type="doi">10.1073/pnas.1610371113</pub-id><pub-id pub-id-type="other">2-s2.0-84994217949</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviles-Olmos</surname><given-names>I.</given-names></name><name><surname>Limousin</surname><given-names>P.</given-names></name><name><surname>Lees</surname><given-names>A.</given-names></name><name><surname>Foltynie</surname><given-names>T.</given-names></name></person-group><article-title>Parkinson&#x02019;s disease, insulin resistance and novel agents of neuroprotection</article-title><source><italic toggle="yes">Brain</italic></source><year>2012</year><volume>136</volume><issue>2</issue><fpage>374</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1093/brain/aws009</pub-id><pub-id pub-id-type="other">2-s2.0-84864855869</pub-id><pub-id pub-id-type="pmid">22344583</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Jousilahti</surname><given-names>P.</given-names></name><name><surname>Bidel</surname><given-names>S.</given-names></name><name><surname>Antikainen</surname><given-names>R.</given-names></name><name><surname>Tuomilehto</surname><given-names>J.</given-names></name></person-group><article-title>Type 2 diabetes and the risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2007</year><volume>30</volume><issue>4</issue><fpage>842</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.2337/dc06-2011</pub-id><pub-id pub-id-type="other">2-s2.0-34147190028</pub-id><pub-id pub-id-type="pmid">17251276</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pablo-Fernandez</surname><given-names>E.</given-names></name><name><surname>Goldacre</surname><given-names>R.</given-names></name><name><surname>Pakpoor</surname><given-names>J.</given-names></name><name><surname>Noyce</surname><given-names>A. J.</given-names></name><name><surname>Warner</surname><given-names>T. T.</given-names></name></person-group><article-title>Association between diabetes and subsequent Parkinson disease</article-title><source><italic toggle="yes">Neurology</italic></source><year>2018</year><volume>91</volume><issue>2</issue><fpage>e139</fpage><lpage>e142</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000005771</pub-id><pub-id pub-id-type="pmid">29898968</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Fu</surname><given-names>D.-l.</given-names></name><name><surname>Li</surname><given-names>H.-q.</given-names></name><name><surname>Liu</surname><given-names>A.-j.</given-names></name><name><surname>Li</surname><given-names>J.-h.</given-names></name><name><surname>Zheng</surname><given-names>G.-q.</given-names></name></person-group><article-title>Diabetes and risk of Parkinson&#x02019;s disease: an updated meta-analysis of case-control studies</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e85781</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085781</pub-id><pub-id pub-id-type="other">2-s2.0-84908160592</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savica</surname><given-names>R.</given-names></name><name><surname>Grossardt</surname><given-names>B. R.</given-names></name><name><surname>Ahlskog</surname><given-names>J. E.</given-names></name><name><surname>Rocca</surname><given-names>W. A.</given-names></name></person-group><article-title>Metabolic markers or conditions preceding Parkinson&#x02019;s disease: a case-control study</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2012</year><volume>27</volume><issue>8</issue><fpage>974</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1002/mds.25016</pub-id><pub-id pub-id-type="other">2-s2.0-84863991205</pub-id><pub-id pub-id-type="pmid">22674432</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woert</surname><given-names>M. H. V.</given-names></name><name><surname>Mueller</surname><given-names>P. S.</given-names></name></person-group><article-title>Glucose, insulin, and free fatty acid metabolism in Parkinson&#x02019;s disease treated with levodopa</article-title><source><italic toggle="yes">Clinical Pharmacology &#x00026; Therapeutics</italic></source><year>1971</year><volume>12</volume><issue>2</issue><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/cpt1971122part2360</pub-id><pub-id pub-id-type="pmid">5577484</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivaprasad</surname><given-names>C.</given-names></name><name><surname>Kalra</surname><given-names>S.</given-names></name></person-group><article-title>Bromocriptine in type 2 diabetes mellitus</article-title><source><italic toggle="yes">Indian Journal of Endocrinology and Metabolism</italic></source><year>2011</year><volume>15</volume><issue>5</issue><fpage>S17</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.4103/2230-8210.83058</pub-id><pub-id pub-id-type="pmid">21847449</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katila</surname><given-names>N.</given-names></name><name><surname>Bhurtel</surname><given-names>S.</given-names></name><name><surname>Shadfar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Metformin lowers <italic>&#x003b1;</italic>-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2017</year><volume>125</volume><fpage>396</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.08.015</pub-id><pub-id pub-id-type="other">2-s2.0-85027587212</pub-id><pub-id pub-id-type="pmid">28807678</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obata</surname><given-names>T.</given-names></name><name><surname>Nakashima</surname><given-names>M.</given-names></name></person-group><article-title>Opening of ATP-sensitive K + (K ATP) channels enhance hydroxyl radical generation induced by MPP + in rat striatum</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2016</year><volume>366</volume><fpage>180</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2016.04.004</pub-id><pub-id pub-id-type="other">2-s2.0-84970997389</pub-id><pub-id pub-id-type="pmid">27288802</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassil</surname><given-names>F.</given-names></name><name><surname>Canron</surname><given-names>M.-H.</given-names></name><name><surname>Vital</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Insulin resistance and exendin-4 treatment for multiple system atrophy</article-title><source><italic toggle="yes">Brain</italic></source><year>2017</year><volume>140</volume><issue>5</issue><fpage>1420</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1093/brain/awx044</pub-id><pub-id pub-id-type="other">2-s2.0-85016941322</pub-id><pub-id pub-id-type="pmid">28334990</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>M.</given-names></name><name><surname>Nissanka</surname><given-names>N.</given-names></name><name><surname>Peralta</surname><given-names>S.</given-names></name><name><surname>Brambilla</surname><given-names>R.</given-names></name><name><surname>Diaz</surname><given-names>F.</given-names></name><name><surname>Moraes</surname><given-names>C.</given-names></name></person-group><article-title>Pioglitazone ameliorates the phenotype of a novel Parkinson&#x02019;s disease mouse model by reducing neuroinflammation</article-title><source><italic toggle="yes">Molecular Neurodegeneration</italic></source><year>2016</year><volume>11</volume><issue>1</issue><fpage>p. 25</fpage><pub-id pub-id-type="doi">10.1186/s13024-016-0090-7</pub-id><pub-id pub-id-type="other">2-s2.0-84962440535</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perier</surname><given-names>C.</given-names></name><name><surname>Tieu</surname><given-names>K.</given-names></name><name><surname>Guegan</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Complex I deficiency primes bax-dependent neuronal apoptosis through mitochondrial oxidative damage</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2005</year><volume>102</volume><issue>52</issue><fpage>19126</fpage><lpage>19131</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508215102</pub-id><pub-id pub-id-type="other">2-s2.0-30044442094</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deas</surname><given-names>E.</given-names></name><name><surname>Piipari</surname><given-names>K.</given-names></name><name><surname>Machhada</surname><given-names>A.</given-names></name><etal/></person-group><article-title>PINK1 deficiency in <italic>&#x003b2;</italic>-cells increases basal insulin secretion and improves glucose tolerance in mice</article-title><source><italic toggle="yes">Open Biology</italic></source><year>2014</year><volume>4</volume><issue>5</issue><fpage>p. 140051</fpage><pub-id pub-id-type="doi">10.1098/rsob.140051</pub-id><pub-id pub-id-type="other">2-s2.0-84900993015</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhai</surname><given-names>Y.-Q.</given-names></name><name><surname>Xu</surname><given-names>L.-L.</given-names></name><etal/></person-group><article-title>Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice</article-title><source><italic toggle="yes">Experimental Neurology</italic></source><year>2014</year><volume>251</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2013.11.001</pub-id><pub-id pub-id-type="other">2-s2.0-84888062088</pub-id><pub-id pub-id-type="pmid">24220636</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>J. K.</given-names></name><name><surname>Bomhoff</surname><given-names>G. L.</given-names></name><name><surname>Gorres</surname><given-names>B. K.</given-names></name><etal/></person-group><article-title>Insulin resistance impairs nigrostriatal dopamine function</article-title><source><italic toggle="yes">Experimental Neurology</italic></source><year>2011</year><volume>231</volume><issue>1</issue><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2011.06.005</pub-id><pub-id pub-id-type="other">2-s2.0-79961030579</pub-id><pub-id pub-id-type="pmid">21703262</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baura</surname><given-names>G. D.</given-names></name><name><surname>Foster</surname><given-names>D. M.</given-names></name><name><surname>Porte</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>1993</year><volume>92</volume><issue>4</issue><fpage>1824</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1172/jci116773</pub-id><pub-id pub-id-type="other">2-s2.0-0027361094</pub-id><pub-id pub-id-type="pmid">8408635</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figlewicz</surname><given-names>D.</given-names></name><name><surname>Brot</surname><given-names>M. D.</given-names></name><name><surname>McCall</surname><given-names>A. L.</given-names></name><name><surname>Szot</surname><given-names>P.</given-names></name></person-group><article-title>Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study</article-title><source><italic toggle="yes">Brain Research</italic></source><year>1996</year><volume>736</volume><issue>1-2</issue><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/s0006-8993(96)00727-5</pub-id><pub-id pub-id-type="pmid">8930308</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renaud</surname><given-names>J.</given-names></name><name><surname>Bassareo</surname><given-names>V.</given-names></name><name><surname>Beaulieu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway</article-title><source><italic toggle="yes">Neurobiology of Aging</italic></source><year>2018</year><volume>69</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.05.010</pub-id><pub-id pub-id-type="other">2-s2.0-85048087597</pub-id><pub-id pub-id-type="pmid">29890391</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>M. E.</given-names></name><name><surname>Butte</surname><given-names>A. J.</given-names></name><name><surname>Crunkhorn</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2003</year><volume>100</volume><issue>14</issue><fpage>8466</fpage><lpage>8471</lpage><pub-id pub-id-type="doi">10.1073/pnas.1032913100</pub-id><pub-id pub-id-type="other">2-s2.0-0037477855</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J.-H.</given-names></name><name><surname>Ko</surname><given-names>H. S.</given-names></name><name><surname>Kang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PARIS (ZNF746) Repression of <italic>PGC-1&#x003b1;</italic> contributes to neurodegeneration in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Cell</italic></source><year>2011</year><volume>144</volume><issue>5</issue><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.010</pub-id><pub-id pub-id-type="other">2-s2.0-79952303794</pub-id><pub-id pub-id-type="pmid">21376232</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mounier</surname><given-names>C.</given-names></name><name><surname>Posner</surname><given-names>B. I.</given-names></name></person-group><article-title>Transcriptional regulation by insulin: from the receptor to the gene</article-title><source><italic toggle="yes">Canadian Journal of Physiology and Pharmacology</italic></source><year>2006</year><volume>84</volume><issue>7</issue><fpage>713</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1139/y05-152</pub-id><pub-id pub-id-type="other">2-s2.0-33845398283</pub-id><pub-id pub-id-type="pmid">16998535</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khang</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Shin</surname><given-names>J.-H.</given-names></name></person-group><article-title>Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2015</year><volume>294</volume><fpage>182</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.03.017</pub-id><pub-id pub-id-type="other">2-s2.0-84925803640</pub-id><pub-id pub-id-type="pmid">25779963</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perruolo</surname><given-names>G.</given-names></name><name><surname>Viggiano</surname><given-names>D.</given-names></name><name><surname>Fiory</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice</article-title><source><italic toggle="yes">Science Reports</italic></source><year>2016</year><volume>6</volume><issue>1</issue><pub-id pub-id-type="publisher-id">29967</pub-id><pub-id pub-id-type="doi">10.1038/srep29967</pub-id><pub-id pub-id-type="other">2-s2.0-84979255279</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>D.-W.</given-names></name><name><surname>Xin</surname><given-names>N.</given-names></name><name><surname>Xie</surname><given-names>B.-J.</given-names></name><etal/></person-group><article-title>Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes</article-title><source><italic toggle="yes">International Journal of Molecular Medicine</italic></source><year>2013</year><volume>33</volume><issue>3</issue><fpage>736</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1604</pub-id><pub-id pub-id-type="other">2-s2.0-84893826232</pub-id><pub-id pub-id-type="pmid">24366308</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>F.</given-names></name><name><surname>Ullah</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2015</year><volume>459</volume><issue>3</issue><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.069</pub-id><pub-id pub-id-type="other">2-s2.0-84931331883</pub-id><pub-id pub-id-type="pmid">25744031</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pablo-Fernandez</surname><given-names>E.</given-names></name><name><surname>Sierra-Hidalgo</surname><given-names>F.</given-names></name><name><surname>Benito-Le&#x000f3;n</surname><given-names>J.</given-names></name><name><surname>Bermejo-Pareja</surname><given-names>F.</given-names></name></person-group><article-title>Association between Parkinson&#x02019;s disease and diabetes: data from NEDICES study</article-title><source><italic toggle="yes">Acta Neurologica Scandinavica</italic></source><year>2017</year><volume>136</volume><issue>6</issue><fpage>732</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1111/ane.12793</pub-id><pub-id pub-id-type="other">2-s2.0-85021316930</pub-id><pub-id pub-id-type="pmid">28653373</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.-W.</given-names></name><name><surname>Hsieh</surname><given-names>T.-F.</given-names></name><name><surname>Li</surname><given-names>C.-I.</given-names></name><etal/></person-group><article-title>Increased risk of Parkinson disease with diabetes mellitus in a population-based study</article-title><source><italic toggle="yes">Medicine</italic></source><year>2017</year><volume>96</volume><issue>3</issue><fpage>p. e5921</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000005921</pub-id><pub-id pub-id-type="other">2-s2.0-85010410432</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Risk of Parkinson disease in diabetes mellitus</article-title><source><italic toggle="yes">Medicine</italic></source><year>2016</year><volume>95</volume><issue>18</issue><fpage>p. e3549</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000003549</pub-id><pub-id pub-id-type="other">2-s2.0-84969862314</pub-id><pub-id pub-id-type="pmid">27149468</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>Y.-H.</given-names></name><name><surname>Chen</surname><given-names>H.-F.</given-names></name><name><surname>Su</surname><given-names>Y.-H.</given-names></name><name><surname>Su</surname><given-names>H.-F.</given-names></name><name><surname>Li</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2012</year><volume>35</volume><issue>5</issue><fpage>1047</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.2337/dc11-1511</pub-id><pub-id pub-id-type="other">2-s2.0-84862110832</pub-id><pub-id pub-id-type="pmid">22432112</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlqvist</surname><given-names>M. L.</given-names></name><name><surname>Lee</surname><given-names>M.-S.</given-names></name><name><surname>Hsu</surname><given-names>C.-C.</given-names></name><name><surname>Chuang</surname><given-names>S.-Y.</given-names></name><name><surname>Lee</surname><given-names>J.-T.</given-names></name><name><surname>Tsai</surname><given-names>H.-N.</given-names></name></person-group><article-title>Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson&#x02019;s disease occurring with type 2 diabetes in a Taiwanese population cohort</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2012</year><volume>18</volume><issue>6</issue><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.03.010</pub-id><pub-id pub-id-type="other">2-s2.0-84862199583</pub-id><pub-id pub-id-type="pmid">22498320</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernhammer</surname><given-names>E.</given-names></name><name><surname>Hansen</surname><given-names>J.</given-names></name><name><surname>Rugbjerg</surname><given-names>K.</given-names></name><name><surname>Wermuth</surname><given-names>L.</given-names></name><name><surname>Ritz</surname><given-names>B.</given-names></name></person-group><article-title>Diabetes and the risk of developing Parkinson&#x02019;s disease in Denmark</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2011</year><volume>34</volume><issue>5</issue><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.2337/dc10-1333</pub-id><pub-id pub-id-type="other">2-s2.0-79956139625</pub-id><pub-id pub-id-type="pmid">21411503</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Diabetes and risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2011</year><volume>34</volume><issue>4</issue><fpage>910</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.2337/dc10-1922</pub-id><pub-id pub-id-type="other">2-s2.0-79956218430</pub-id><pub-id pub-id-type="pmid">21378214</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Fukushima</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Case-control study of risk of Parkinson&#x02019;s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2010</year><volume>293</volume><issue>1-2</issue><fpage>82</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2010.03.002</pub-id><pub-id pub-id-type="other">2-s2.0-77952100141</pub-id><pub-id pub-id-type="pmid">20347450</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amelio</surname><given-names>M.</given-names></name><name><surname>Ragonese</surname><given-names>P.</given-names></name><name><surname>Callari</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Diabetes preceding Parkinson&#x02019;s disease onset: a case-control study</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2009</year><volume>15</volume><issue>9</issue><fpage>660</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.02.013</pub-id><pub-id pub-id-type="other">2-s2.0-70350173257</pub-id><pub-id pub-id-type="pmid">19356970</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibson</surname><given-names>C. L.</given-names></name><name><surname>Maraganore</surname><given-names>D. M.</given-names></name><name><surname>Bower</surname><given-names>J. H.</given-names></name><name><surname>Ransom</surname><given-names>J. E.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>P. C.</given-names></name><name><surname>Rocca</surname><given-names>W. A.</given-names></name></person-group><article-title>Comorbid conditions associated with Parkinson&#x02019;s disease: a population-based study</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2006</year><volume>21</volume><issue>4</issue><fpage>446</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/mds.20685</pub-id><pub-id pub-id-type="other">2-s2.0-33646254633</pub-id><pub-id pub-id-type="pmid">16161155</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>K. M.</given-names></name><name><surname>Smith-Weller</surname><given-names>T.</given-names></name><name><surname>Franklin</surname><given-names>G. M.</given-names></name><name><surname>Longstreth</surname><given-names>W. T.</given-names></name><name><surname>Swanson</surname><given-names>P. D.</given-names></name><name><surname>Checkoway</surname><given-names>H.</given-names></name></person-group><article-title>Diabetes, smoking, and other medical conditions in relation to Parkinson&#x02019;s disease risk</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2006</year><volume>12</volume><issue>3</issue><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2005.09.004</pub-id><pub-id pub-id-type="other">2-s2.0-33645975176</pub-id><pub-id pub-id-type="pmid">16364673</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herishanu</surname><given-names>Y. O.</given-names></name><name><surname>Medvedovski</surname><given-names>M.</given-names></name><name><surname>Goldsmith</surname><given-names>J. R.</given-names></name><name><surname>Kordysh</surname><given-names>E.</given-names></name></person-group><article-title>A case-control study of Parkinson&#x02019;s disease in urban population of Southern Israel</article-title><source><italic toggle="yes">Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques</italic></source><year>2001</year><volume>28</volume><issue>2</issue><fpage>144</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1017/s0317167100052835</pub-id><pub-id pub-id-type="other">2-s2.0-0035018975</pub-id><pub-id pub-id-type="pmid">11383940</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>N.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>McCullough</surname><given-names>M. L.</given-names></name><etal/></person-group><article-title>Obesity, diabetes, and risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2011</year><volume>26</volume><issue>12</issue><fpage>2253</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1002/mds.23855</pub-id><pub-id pub-id-type="other">2-s2.0-80055084206</pub-id><pub-id pub-id-type="pmid">21739472</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driver</surname><given-names>J. A.</given-names></name><name><surname>Smith</surname><given-names>A.</given-names></name><name><surname>Buring</surname><given-names>J. E.</given-names></name><name><surname>Gaziano</surname><given-names>J. M.</given-names></name><name><surname>Kurth</surname><given-names>T.</given-names></name><name><surname>Logroscino</surname><given-names>G.</given-names></name></person-group><article-title>Prospective cohort study of type 2 diabetes and the risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2008</year><volume>31</volume><issue>10</issue><fpage>2003</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.2337/dc08-0688</pub-id><pub-id pub-id-type="other">2-s2.0-56149110407</pub-id><pub-id pub-id-type="pmid">18599528</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>K. C.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Schwarzschild</surname><given-names>M.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group><article-title>Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease</article-title><source><italic toggle="yes">Neurology</italic></source><year>2007</year><volume>69</volume><issue>17</issue><fpage>1688</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271883.45010.8a</pub-id><pub-id pub-id-type="other">2-s2.0-36048933577</pub-id><pub-id pub-id-type="pmid">17761552</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>C.</given-names></name><name><surname>Brobert</surname><given-names>G. P.</given-names></name><name><surname>Johansson</surname><given-names>S.</given-names></name><name><surname>Jick</surname><given-names>S. S.</given-names></name><name><surname>Meier</surname><given-names>C. R.</given-names></name></person-group><article-title>Diabetes in patients with idiopathic Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2008</year><volume>31</volume><issue>9</issue><fpage>1808</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.2337/dc08-0479</pub-id><pub-id pub-id-type="other">2-s2.0-56149114786</pub-id><pub-id pub-id-type="pmid">18559656</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scigliano</surname><given-names>G.</given-names></name><name><surname>Musicco</surname><given-names>M.</given-names></name><name><surname>Soliveri</surname><given-names>P.</given-names></name><name><surname>Piccolo</surname><given-names>I.</given-names></name><name><surname>Ronchetti</surname><given-names>G.</given-names></name><name><surname>Girotti</surname><given-names>F.</given-names></name></person-group><article-title>Reduced risk factors for vascular disorders in Parkinson disease patients</article-title><source><italic toggle="yes">Stroke</italic></source><year>2006</year><volume>37</volume><issue>5</issue><fpage>1184</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1161/01.str.0000217384.03237.9c</pub-id><pub-id pub-id-type="other">2-s2.0-33646697974</pub-id><pub-id pub-id-type="pmid">16574924</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pressley</surname><given-names>J. C.</given-names></name><name><surname>Louis</surname><given-names>E. D.</given-names></name><name><surname>Tang</surname><given-names>M.-X.</given-names></name><etal/></person-group><article-title>The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism</article-title><source><italic toggle="yes">Neurology</italic></source><year>2003</year><volume>60</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1212/wnl.60.1.87</pub-id><pub-id pub-id-type="other">2-s2.0-0037435524</pub-id><pub-id pub-id-type="pmid">12525724</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S. J.</given-names></name><name><surname>Kim</surname><given-names>M.-J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association of type 2 diabetes GWAS loci and the risk of Parkinson&#x02019;s and Alzheimer&#x02019;s diseases</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2015</year><volume>21</volume><issue>12</issue><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.10.010</pub-id><pub-id pub-id-type="other">2-s2.0-84955735405</pub-id><pub-id pub-id-type="pmid">26499758</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>J. A.</given-names></name><name><surname>Scherzer</surname><given-names>C. R.</given-names></name><name><surname>Potashkin</surname><given-names>J. A.</given-names></name></person-group><article-title>Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>10</issue><pub-id pub-id-type="publisher-id">e109042</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109042</pub-id><pub-id pub-id-type="other">2-s2.0-84915744886</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>J. A.</given-names></name><name><surname>Potashkin</surname><given-names>J. A.</given-names></name></person-group><article-title>Integrative network analysis unveils convergent molecular pathways in Parkinson&#x02019;s disease and diabetes</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>12</issue><pub-id pub-id-type="publisher-id">e83940</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0083940</pub-id><pub-id pub-id-type="other">2-s2.0-84893511983</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takasaki</surname><given-names>S.</given-names></name></person-group><article-title>Mitochondrial haplogroups associated with Japanese centenarians, Alzheimer&#x02019;s patients, Parkinson&#x02019;s patients, type 2 diabetic patients and healthy non-obese young males</article-title><source><italic toggle="yes">Journal of Genetics and Genomics</italic></source><year>2009</year><volume>36</volume><issue>7</issue><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/s1673-8527(08)60132-0</pub-id><pub-id pub-id-type="other">2-s2.0-67650976561</pub-id><pub-id pub-id-type="pmid">19631917</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>M.</given-names></name><name><surname>Foo</surname><given-names>H.</given-names></name><name><surname>Chander</surname><given-names>R. J.</given-names></name><etal/></person-group><article-title>Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2017</year><volume>377</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2017.04.010</pub-id><pub-id pub-id-type="other">2-s2.0-85017359575</pub-id><pub-id pub-id-type="pmid">28477681</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrou</surname><given-names>M.</given-names></name><name><surname>Davatzikos</surname><given-names>C.</given-names></name><name><surname>Hsieh</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Diabetes, gray matter loss, and cognition in the setting of Parkinson disease</article-title><source><italic toggle="yes">Academic Radiology</italic></source><year>2016</year><volume>23</volume><issue>5</issue><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.acra.2015.07.014</pub-id><pub-id pub-id-type="other">2-s2.0-84957916449</pub-id><pub-id pub-id-type="pmid">26874576</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnen</surname><given-names>N. I.</given-names></name><name><surname>Kotagal</surname><given-names>V.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M. L. T. M.</given-names></name><etal/></person-group><article-title>Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2014</year><volume>20</volume><issue>12</issue><fpage>1394</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.10.008</pub-id><pub-id pub-id-type="other">2-s2.0-84915757039</pub-id><pub-id pub-id-type="pmid">25454317</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed Ibrahim</surname><given-names>N.</given-names></name><name><surname>Ramli</surname><given-names>R.</given-names></name><name><surname>Koya Kutty</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>S. A.</given-names></name></person-group><article-title>Earlier onset of motor complications in Parkinson&#x02019;s patients with comorbid diabetes mellitus</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2018</year><volume>33</volume><issue>12</issue><fpage>1967</fpage><lpage>1968</lpage><pub-id pub-id-type="doi">10.1002/mds.27526</pub-id><pub-id pub-id-type="other">2-s2.0-85056474897</pub-id><pub-id pub-id-type="pmid">30427552</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>G.</given-names></name><name><surname>Polychronis</surname><given-names>S.</given-names></name><name><surname>Wilson</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Diabetes mellitus and Parkinson disease</article-title><source><italic toggle="yes">Neurology</italic></source><year>2018</year><volume>90</volume><issue>19</issue><fpage>e1654</fpage><lpage>e1662</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000005475</pub-id><pub-id pub-id-type="pmid">29626177</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotagal</surname><given-names>V.</given-names></name><name><surname>Albin</surname><given-names>R. L.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M. L. T. M.</given-names></name><name><surname>Koeppe</surname><given-names>R. A.</given-names></name><name><surname>Frey</surname><given-names>K. A.</given-names></name><name><surname>Bohnen</surname><given-names>N. I.</given-names></name></person-group><article-title>Diabetes is associated with postural instability and gait difficulty in Parkinson disease</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2013</year><volume>19</volume><issue>5</issue><fpage>522</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.01.016</pub-id><pub-id pub-id-type="other">2-s2.0-84875528944</pub-id><pub-id pub-id-type="pmid">23462483</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cereda</surname><given-names>E.</given-names></name><name><surname>Barichella</surname><given-names>M.</given-names></name><name><surname>Cassani</surname><given-names>E.</given-names></name><name><surname>Caccialanza</surname><given-names>R.</given-names></name><name><surname>Pezzoli</surname><given-names>G.</given-names></name></person-group><article-title>Clinical features of Parkinson disease when onset of diabetes came first: a case-control study</article-title><source><italic toggle="yes">Neurology</italic></source><year>2012</year><volume>78</volume><issue>19</issue><fpage>1507</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1212/wnl.0b013e3182553cc9</pub-id><pub-id pub-id-type="other">2-s2.0-84863625218</pub-id><pub-id pub-id-type="pmid">22539572</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuing</surname><given-names>N.</given-names></name><name><surname>Best</surname><given-names>F.</given-names></name><name><surname>Dapp</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DPV initiative and the German BMBF competence network diabetes mellitus multicentre analysis of 178,992 type 2 diabetes patients revealed better metabolic control despite higher rates of hypertension, stroke, dementia and repeated inpatient care in patients with comorbid Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2013</year><volume>19</volume><issue>7</issue><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.03.011</pub-id><pub-id pub-id-type="other">2-s2.0-84878219906</pub-id><pub-id pub-id-type="pmid">23615668</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosati</surname><given-names>G.</given-names></name><name><surname>Maioli</surname><given-names>M.</given-names></name><name><surname>Aiello</surname><given-names>I.</given-names></name><name><surname>Farris</surname><given-names>A.</given-names></name><name><surname>Agnetti</surname><given-names>V.</given-names></name></person-group><article-title>Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">European Neurology</italic></source><year>1976</year><volume>14</volume><issue>3</issue><fpage>229</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1159/000114744</pub-id><pub-id pub-id-type="other">2-s2.0-0017075174</pub-id><pub-id pub-id-type="pmid">1278195</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamarthi</surname><given-names>B.</given-names></name><name><surname>Cincotta</surname><given-names>A. H.</given-names></name></person-group><article-title>Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin</article-title><source><italic toggle="yes">Postgraduate Medicine</italic></source><year>2017</year><volume>129</volume><issue>4</issue><fpage>446</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1080/00325481.2017.1315290</pub-id><pub-id pub-id-type="other">2-s2.0-85017465844</pub-id><pub-id pub-id-type="pmid">28374645</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roe</surname><given-names>E. D.</given-names></name><name><surname>Chamarthi</surname><given-names>B.</given-names></name><name><surname>Raskin</surname><given-names>P.</given-names></name></person-group><article-title>Impact of bromocriptine-QR Therapy on glycemic control and daily insulin requirement in type 2 diabetes mellitus subjects whose dysglycemia is poorly controlled on high-dose insulin: a pilot study</article-title><source><italic toggle="yes">Journal of Diabetes Research</italic></source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2015/834903</pub-id><pub-id pub-id-type="other">2-s2.0-84929352889</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Sengupta</surname><given-names>N.</given-names></name><name><surname>Sahana</surname><given-names>P.</given-names></name><name><surname>Giri</surname><given-names>D.</given-names></name><name><surname>Sengupta</surname><given-names>P.</given-names></name><name><surname>Das</surname><given-names>N.</given-names></name></person-group><article-title>Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial</article-title><source><italic toggle="yes">Indian Journal of Pharmacology</italic></source><year>2014</year><volume>46</volume><issue>1</issue><fpage>p. 24</fpage><pub-id pub-id-type="doi">10.4103/0253-7613.125160</pub-id><pub-id pub-id-type="other">2-s2.0-84893325293</pub-id><pub-id pub-id-type="pmid">24550580</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaziano</surname><given-names>J. M.</given-names></name><name><surname>Cincotta</surname><given-names>A. H.</given-names></name><name><surname>Vinik</surname><given-names>A.</given-names></name><name><surname>Blonde</surname><given-names>L.</given-names></name><name><surname>Bohannon</surname><given-names>N.</given-names></name><name><surname>Scranton</surname><given-names>R.</given-names></name></person-group><article-title>Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects</article-title><source><italic toggle="yes">Journal of the American Heart Association</italic></source><year>2012</year><volume>1</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e002279</pub-id><pub-id pub-id-type="doi">10.1161/jaha.112.002279</pub-id><pub-id pub-id-type="other">2-s2.0-84877038797</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinik</surname><given-names>A.</given-names></name><name><surname>Cincotta</surname><given-names>A.</given-names></name><name><surname>Scranton</surname><given-names>R.</given-names></name><name><surname>Bohannon</surname><given-names>N.</given-names></name><name><surname>Ezrokhi</surname><given-names>M.</given-names></name><name><surname>Gaziano</surname><given-names>J.</given-names></name></person-group><article-title>Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents</article-title><source><italic toggle="yes">Endocrine Practice</italic></source><year>2012</year><volume>18</volume><issue>6</issue><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.4158/ep12187.or</pub-id><pub-id pub-id-type="other">2-s2.0-84871373150</pub-id><pub-id pub-id-type="pmid">23186965</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijl</surname><given-names>H.</given-names></name><name><surname>Ohashi</surname><given-names>S.</given-names></name><name><surname>Matsuda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Bromocriptine: a novel approach to the treatment of type 2 diabetes</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2000</year><volume>23</volume><issue>8</issue><fpage>1154</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.8.1154</pub-id><pub-id pub-id-type="other">2-s2.0-0033861067</pub-id><pub-id pub-id-type="pmid">10937514</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezrokhi</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Trubitsyna</surname><given-names>Y.</given-names></name><name><surname>Cincotta</surname><given-names>A. H.</given-names></name></person-group><article-title>Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats</article-title><source><italic toggle="yes">Diabetology &#x00026; Metabolic Syndrome</italic></source><year>2014</year><volume>6</volume><issue>1</issue><fpage>p. 104</fpage><pub-id pub-id-type="doi">10.1186/1758-5996-6-104</pub-id><pub-id pub-id-type="other">2-s2.0-84928619466</pub-id><pub-id pub-id-type="pmid">25937836</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Cincotta</surname><given-names>A. H.</given-names></name></person-group><article-title>Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster</article-title><source><italic toggle="yes">Chronobiology International</italic></source><year>2000</year><volume>17</volume><issue>2</issue><fpage>155</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1081/cbi-100101040</pub-id><pub-id pub-id-type="other">2-s2.0-0034069791</pub-id><pub-id pub-id-type="pmid">10757461</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Meier</surname><given-names>A. H.</given-names></name><name><surname>Cincotta</surname><given-names>A. H.</given-names></name></person-group><article-title>Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters</article-title><source><italic toggle="yes">Neuroendocrinology</italic></source><year>1998</year><volume>68</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1159/000054344</pub-id><pub-id pub-id-type="other">2-s2.0-0031807188</pub-id><pub-id pub-id-type="pmid">9695933</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cincotta</surname><given-names>A. H.</given-names></name><name><surname>Meier</surname><given-names>A. H.</given-names></name></person-group><article-title>Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (<italic>Mesocricetus auratus</italic>)</article-title><source><italic toggle="yes">Metabolism</italic></source><year>1995</year><volume>44</volume><issue>10</issue><fpage>1349</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1016/0026-0495(95)90041-1</pub-id><pub-id pub-id-type="other">2-s2.0-0029553959</pub-id><pub-id pub-id-type="pmid">7476296</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>Y.-K.</given-names></name><name><surname>Park</surname><given-names>H.-Y.</given-names></name><name><surname>Go</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Metformin inhibits the development of l-DOPA-induced dyskinesia in a murine model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Molecular Neurobiology</italic></source><year>2018</year><volume>55</volume><issue>7</issue><fpage>5715</fpage><lpage>5726</lpage><pub-id pub-id-type="doi">10.1007/s12035-017-0752-7</pub-id><pub-id pub-id-type="other">2-s2.0-85031943315</pub-id><pub-id pub-id-type="pmid">29039022</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismaiel</surname><given-names>A. A. K.</given-names></name><name><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name><surname>Santiago</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system</article-title><source><italic toggle="yes">Toxicology and Applied Pharmacology</italic></source><year>2016</year><volume>298</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2016.03.004</pub-id><pub-id pub-id-type="other">2-s2.0-84960927086</pub-id><pub-id pub-id-type="pmid">26971375</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>S. P.</given-names></name><name><surname>Jain</surname><given-names>P. D.</given-names></name><name><surname>Ghumatkar</surname><given-names>P. J.</given-names></name><name><surname>Tambe</surname><given-names>R.</given-names></name><name><surname>Sathaye</surname><given-names>S.</given-names></name></person-group><article-title>Neuroprotective effect of metformin in MPTP-induced Parkinson&#x02019;s disease in mice</article-title><source><italic toggle="yes">Neuroscience</italic></source><year>2014</year><volume>277</volume><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.07.046</pub-id><pub-id pub-id-type="other">2-s2.0-84907032242</pub-id><pub-id pub-id-type="pmid">25108167</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.-S.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Jeong</surname><given-names>J.-W.</given-names></name></person-group><article-title>AMP-activated protein kinase is activated in Parkinson&#x02019;s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2010</year><volume>391</volume><issue>1</issue><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.11.022</pub-id><pub-id pub-id-type="other">2-s2.0-72949122084</pub-id><pub-id pub-id-type="pmid">19903456</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuan</surname><given-names>Y.-C.</given-names></name><name><surname>Huang</surname><given-names>K.-W.</given-names></name><name><surname>Lin</surname><given-names>C.-L.</given-names></name><name><surname>Hu</surname><given-names>C.-J.</given-names></name><name><surname>Kao</surname><given-names>C.-H.</given-names></name></person-group><article-title>Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus</article-title><source><italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>2017</year><volume>79</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.06.002</pub-id><pub-id pub-id-type="other">2-s2.0-85021071042</pub-id><pub-id pub-id-type="pmid">28583443</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>J. C.</given-names></name><name><surname>Zimprich</surname><given-names>A.</given-names></name><name><surname>Carvajal Berrio</surname><given-names>D. A.</given-names></name><etal/></person-group><article-title>Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Brain</italic></source><year>2017</year><volume>140</volume><issue>9</issue><fpage>2444</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1093/brain/awx202</pub-id><pub-id pub-id-type="other">2-s2.0-85031772069</pub-id><pub-id pub-id-type="pmid">29050400</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>C.</given-names></name></person-group><article-title>Semaglutide is neuroprotective and reduces <italic>&#x003b1;</italic>-synuclein levels in the chronic MPTP mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Parkinson&#x02019;s Disease</italic></source><year>2019</year><volume>9</volume><issue>1</issue><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.3233/jpd-181503</pub-id><pub-id pub-id-type="other">2-s2.0-85061176006</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Feng</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson&#x02019;s disease by reducing chronic inflammation in the brain</article-title><source><italic toggle="yes">NeuroReport</italic></source><year>2016</year><volume>27</volume><issue>6</issue><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1097/wnr.0000000000000548</pub-id><pub-id pub-id-type="other">2-s2.0-84959239661</pub-id><pub-id pub-id-type="pmid">26918675</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>H. H.</given-names></name><name><surname>Fabricius</surname><given-names>K.</given-names></name><name><surname>Barkholt</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Brain Research</italic></source><year>2016</year><volume>1646</volume><fpage>354</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2016.05.038</pub-id><pub-id pub-id-type="other">2-s2.0-84975699602</pub-id><pub-id pub-id-type="pmid">27233809</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name></person-group><article-title>Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Endocrinology</italic></source><year>2009</year><volume>202</volume><issue>3</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1677/joe-09-0132</pub-id><pub-id pub-id-type="other">2-s2.0-70349334516</pub-id><pub-id pub-id-type="pmid">19570816</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Kindy</surname><given-names>M. S.</given-names></name><name><surname>Harvey</surname><given-names>B. K.</given-names></name><etal/></person-group><article-title>GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2009</year><volume>106</volume><issue>4</issue><fpage>1285</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806720106</pub-id><pub-id pub-id-type="other">2-s2.0-59049087723</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertilsson</surname><given-names>G.</given-names></name><name><surname>Patrone</surname><given-names>C.</given-names></name><name><surname>Zachrisson</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neuroscience Research</italic></source><year>2008</year><volume>86</volume><issue>2</issue><fpage>326</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1002/jnr.21483</pub-id><pub-id pub-id-type="other">2-s2.0-38849196303</pub-id><pub-id pub-id-type="pmid">17803225</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkavyi</surname><given-names>A.</given-names></name><name><surname>Abuirmeileh</surname><given-names>A.</given-names></name><name><surname>Lever</surname><given-names>R.</given-names></name><name><surname>Kingsbury</surname><given-names>A. E.</given-names></name><name><surname>Biggs</surname><given-names>C. S.</given-names></name><name><surname>Whitton</surname><given-names>P. S.</given-names></name></person-group><article-title>Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neuroinflammation</italic></source><year>2008</year><volume>5</volume><issue>1</issue><fpage>p. 19</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-5-19</pub-id><pub-id pub-id-type="other">2-s2.0-45549108268</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athauda</surname><given-names>D.</given-names></name><name><surname>Maclagan</surname><given-names>K.</given-names></name><name><surname>Skene</surname><given-names>S. S.</given-names></name><etal/></person-group><article-title>Exenatide once weekly versus placebo in Parkinson&#x02019;s disease: a randomised, double-blind, placebo-controlled trial</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2017</year><volume>390</volume><issue>10103</issue><fpage>1664</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(17)31585-4</pub-id><pub-id pub-id-type="other">2-s2.0-85028049108</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviles-Olmos</surname><given-names>I.</given-names></name><name><surname>Dickson</surname><given-names>J.</given-names></name><name><surname>Kefalopoulou</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Parkinson&#x02019;s Disease</italic></source><year>2015</year><volume>4</volume><issue>3</issue><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.3233/jpd-140364</pub-id><pub-id pub-id-type="other">2-s2.0-84904126994</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviles-Olmos</surname><given-names>I.</given-names></name><name><surname>Dickson</surname><given-names>J.</given-names></name><name><surname>Kefalopoulou</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Exenatide and the treatment of patients with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>2013</year><volume>123</volume><issue>6</issue><fpage>2730</fpage><lpage>2736</lpage><pub-id pub-id-type="doi">10.1172/jci68295</pub-id><pub-id pub-id-type="other">2-s2.0-84878542289</pub-id><pub-id pub-id-type="pmid">23728174</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalewa</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>M. K.</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>C.</given-names></name></person-group><article-title>Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2016</year><volume>139</volume><issue>1</issue><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/jnc.13736</pub-id><pub-id pub-id-type="other">2-s2.0-84983398492</pub-id><pub-id pub-id-type="pmid">27412483</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells</article-title><source><italic toggle="yes">Journal of Pharmacology and Experimental Therapeutics</italic></source><year>2002</year><volume>300</volume><issue>3</issue><fpage>958</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1124/jpet.300.3.958</pub-id><pub-id pub-id-type="other">2-s2.0-0036182251</pub-id><pub-id pub-id-type="pmid">11861804</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2018</year><volume>133</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.02.012</pub-id><pub-id pub-id-type="other">2-s2.0-85042363755</pub-id><pub-id pub-id-type="pmid">29462693</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>C.</given-names></name></person-group><article-title>D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson&#x02019;s disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation</article-title><source><italic toggle="yes">European Journal of Pharmacology</italic></source><year>2017</year><volume>797</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2016.11.050</pub-id><pub-id pub-id-type="other">2-s2.0-85011116126</pub-id><pub-id pub-id-type="pmid">27913104</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelsalam</surname><given-names>R. M.</given-names></name><name><surname>Safar</surname><given-names>M. M.</given-names></name></person-group><article-title>Neuroprotective effects of vildagliptin in rat rotenone Parkinson&#x02019;s disease model: role of RAGE-NF&#x003ba;B and Nrf2-antioxidant signaling pathways</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2015</year><volume>133</volume><issue>5</issue><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1111/jnc.13087</pub-id><pub-id pub-id-type="other">2-s2.0-84928009282</pub-id><pub-id pub-id-type="pmid">25752913</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pipatpiboon</surname><given-names>N.</given-names></name><name><surname>Pintana</surname><given-names>H.</given-names></name><name><surname>Pratchayasakul</surname><given-names>W.</given-names></name><name><surname>Chattipakorn</surname><given-names>N.</given-names></name><name><surname>Chattipakorn</surname><given-names>S. C.</given-names></name></person-group><article-title>DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption</article-title><source><italic toggle="yes">European Journal of Neuroscience</italic></source><year>2012</year><volume>37</volume><issue>5</issue><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1111/ejn.12088</pub-id><pub-id pub-id-type="other">2-s2.0-84874525661</pub-id><pub-id pub-id-type="pmid">23240760</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svenningsson</surname><given-names>P.</given-names></name><name><surname>Wirdefeldt</surname><given-names>K.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Reduced incidence of Parkinson&#x02019;s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2016</year><volume>31</volume><issue>9</issue><fpage>1422</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1002/mds.26734</pub-id><pub-id pub-id-type="other">2-s2.0-84985914579</pub-id><pub-id pub-id-type="pmid">27431803</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>J.</given-names></name><name><surname>Klorig</surname><given-names>D. C.</given-names></name><name><surname>Bloomquist</surname><given-names>J. R.</given-names></name></person-group><article-title>Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo</article-title><source><italic toggle="yes">NeuroToxicology</italic></source><year>2006</year><volume>27</volume><issue>5</issue><fpage>826</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2006.04.004</pub-id><pub-id pub-id-type="other">2-s2.0-33747164173</pub-id><pub-id pub-id-type="pmid">16725203</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>K.-K.</given-names></name><name><surname>Truong</surname><given-names>D. D.</given-names></name></person-group><article-title>Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: Therapeutic implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neuroscience Research</italic></source><year>2002</year><volume>69</volume><issue>4</issue><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/jnr.10309</pub-id><pub-id pub-id-type="other">2-s2.0-0037102937</pub-id><pub-id pub-id-type="pmid">12210849</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A. A.</given-names></name><name><surname>Morgese</surname><given-names>M. G.</given-names></name><name><surname>Pisanu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2015</year><volume>74</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.11.024</pub-id><pub-id pub-id-type="other">2-s2.0-84919359735</pub-id><pub-id pub-id-type="pmid">25486547</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Ji</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2015</year><volume>93</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.01.030</pub-id><pub-id pub-id-type="other">2-s2.0-84923625000</pub-id><pub-id pub-id-type="pmid">25680233</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbiero</surname><given-names>J. K.</given-names></name><name><surname>Santiago</surname><given-names>R. M.</given-names></name><name><surname>Persike</surname><given-names>D. S.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine</article-title><source><italic toggle="yes">Behavioural Brain Research</italic></source><year>2014</year><volume>274</volume><fpage>390</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2014.08.014</pub-id><pub-id pub-id-type="other">2-s2.0-84908667745</pub-id><pub-id pub-id-type="pmid">25127682</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisanu</surname><given-names>A.</given-names></name><name><surname>Lecca</surname><given-names>D.</given-names></name><name><surname>Mulas</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-&#x003b3; agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2014</year><volume>71</volume><fpage>280</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.08.011</pub-id><pub-id pub-id-type="other">2-s2.0-84908084191</pub-id><pub-id pub-id-type="pmid">25134730</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>L. P.</given-names></name><name><surname>Crook</surname><given-names>B.</given-names></name><name><surname>Hows</surname><given-names>M. E.</given-names></name><etal/></person-group><article-title>The PPAR&#x003b3; agonist pioglitazone is effective in the MPTP mouse model of Parkinson&#x02019;s disease through inhibition of monoamine oxidase B</article-title><source><italic toggle="yes">British Journal of Pharmacology</italic></source><year>2008</year><volume>154</volume><issue>1</issue><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.78</pub-id><pub-id pub-id-type="other">2-s2.0-42949100802</pub-id><pub-id pub-id-type="pmid">18332857</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>R. L.</given-names></name><name><surname>Dragicevic</surname><given-names>N.</given-names></name><name><surname>Seifert</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2007</year><volume>100</volume><issue>5</issue><fpage>1375</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04327.x</pub-id><pub-id pub-id-type="other">2-s2.0-33847005101</pub-id><pub-id pub-id-type="pmid">17254027</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehmer</surname><given-names>T.</given-names></name><name><surname>Heneka</surname><given-names>M. T.</given-names></name><name><surname>Sastre</surname><given-names>M.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name><name><surname>Schulz</surname><given-names>J. B.</given-names></name></person-group><article-title>Protection by pioglitazone in the MPTP model of Parkinson&#x02019;s disease correlates with I&#x003ba;B<italic>&#x003b1;</italic> induction and block of NF&#x003ba;B and iNOS activation</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2003</year><volume>88</volume><issue>2</issue><fpage>494</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.02210.x</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breidert</surname><given-names>T.</given-names></name><name><surname>Callebert</surname><given-names>J.</given-names></name><name><surname>Heneka</surname><given-names>M. T.</given-names></name><name><surname>Landreth</surname><given-names>G.</given-names></name><name><surname>Launay</surname><given-names>J. M.</given-names></name><name><surname>Hirsch</surname><given-names>E. C.</given-names></name></person-group><article-title>Protective action of the peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> agonist pioglitazone in a mouse model of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neurochemistry</italic></source><year>2002</year><volume>82</volume><issue>3</issue><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00990.x</pub-id><pub-id pub-id-type="other">2-s2.0-0036326074</pub-id><pub-id pub-id-type="pmid">12153485</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brakedal</surname><given-names>B.</given-names></name><name><surname>Fl&#x000f8;nes</surname><given-names>I.</given-names></name><name><surname>Reiter</surname><given-names>S. F.</given-names></name><etal/></person-group><article-title>Glitazone use associated with reduced risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2017</year><volume>32</volume><issue>11</issue><fpage>1594</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1002/mds.27128</pub-id><pub-id pub-id-type="other">2-s2.0-85028601232</pub-id><pub-id pub-id-type="pmid">28861893</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brauer</surname><given-names>R.</given-names></name><name><surname>Bhaskaran</surname><given-names>K.</given-names></name><name><surname>Chaturvedi</surname><given-names>N.</given-names></name><name><surname>Dexter</surname><given-names>D. T.</given-names></name><name><surname>Smeeth</surname><given-names>L.</given-names></name><name><surname>Douglas</surname><given-names>I.</given-names></name></person-group><article-title>Glitazone treatment and incidence of Parkinson&#x02019;s disease among people with diabetes: a retrospective cohort study</article-title><source><italic toggle="yes">PLOS Medicine</italic></source><year>2015</year><volume>12</volume><issue>7</issue><pub-id pub-id-type="publisher-id">e1001854</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001854</pub-id><pub-id pub-id-type="other">2-s2.0-84938717912</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><collab>NINDS Exploratory Trials in Parkinson Disease FS-ZONE, Investigators</collab><article-title>Pioglitazone in early Parkinson&#x02019;s disease: a phase 2, multicentre, double-blind, randomised trial</article-title><source><italic toggle="yes">The Lancet Neurology</italic></source><year>2015</year><volume>14</volume><issue>8</issue><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(15)00144-1</pub-id><pub-id pub-id-type="other">2-s2.0-84937520622</pub-id><pub-id pub-id-type="pmid">26116315</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>D. K.</given-names></name><name><surname>Simuni</surname><given-names>T.</given-names></name><name><surname>Elm</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Peripheral biomarkers of Parkinson&#x02019;s disease progression and pioglitazone effects</article-title><source><italic toggle="yes">Journal of Parkinson&#x02019;s Disease</italic></source><year>2015</year><volume>5</volume><issue>4</issue><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.3233/jpd-150666</pub-id><pub-id pub-id-type="other">2-s2.0-84946603008</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>T. W.</given-names></name><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Shim</surname><given-names>W. S.</given-names></name><etal/></person-group><article-title>Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production</article-title><source><italic toggle="yes">Journal of the Neurological Sciences</italic></source><year>2007</year><volume>253</volume><issue>1-2</issue><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2006.11.020</pub-id><pub-id pub-id-type="other">2-s2.0-33846610917</pub-id><pub-id pub-id-type="pmid">17266988</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Bing</surname><given-names>G.</given-names></name></person-group><article-title>Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-&#x003ba;B and JNK activation and suppression of COX-2 activity</article-title><source><italic toggle="yes">Journal of Neuroimmunology</italic></source><year>2007</year><volume>192</volume><issue>1-2</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.09.029</pub-id><pub-id pub-id-type="other">2-s2.0-36749097843</pub-id><pub-id pub-id-type="pmid">17976742</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cereda</surname><given-names>E.</given-names></name><name><surname>Barichella</surname><given-names>M.</given-names></name><name><surname>Pedrolli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Diabetes and risk of Parkinson&#x02019;s disease: a systematic review and meta-analysis</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2011</year><volume>34</volume><issue>12</issue><fpage>2614</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.2337/dc11-1584</pub-id><pub-id pub-id-type="other">2-s2.0-84859049352</pub-id><pub-id pub-id-type="pmid">22110170</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tysnes</surname><given-names>O.-B.</given-names></name><name><surname>Storstein</surname><given-names>A.</given-names></name></person-group><article-title>Epidemiology of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>2017</year><volume>124</volume><issue>8</issue><fpage>901</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1007/s00702-017-1686-y</pub-id><pub-id pub-id-type="other">2-s2.0-85011299976</pub-id><pub-id pub-id-type="pmid">28150045</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Real</surname><given-names>J. M.</given-names></name><name><surname>Lopez-Bermejo</surname><given-names>A.</given-names></name><name><surname>Ricart</surname><given-names>W.</given-names></name></person-group><article-title>Cross-talk between iron metabolism and diabetes</article-title><source><italic toggle="yes">Diabetes</italic></source><year>2002</year><volume>51</volume><issue>8</issue><fpage>2348</fpage><lpage>2354</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.8.2348</pub-id><pub-id pub-id-type="other">2-s2.0-0036325879</pub-id><pub-id pub-id-type="pmid">12145144</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>S. L.</given-names></name><name><surname>Ritz</surname><given-names>B.</given-names></name></person-group><article-title>Genetics of iron regulation and the possible role of iron in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2008</year><volume>32</volume><issue>2</issue><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2008.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-53749096620</pub-id><pub-id pub-id-type="pmid">18675357</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirtori</surname><given-names>C. R.</given-names></name><name><surname>Bolme</surname><given-names>P.</given-names></name><name><surname>Azarnoff</surname><given-names>D. L.</given-names></name></person-group><article-title>Metabolic responses to acute and chronic L-dopa administration in patients with Parkinsonism</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>1972</year><volume>287</volume><issue>15</issue><fpage>729</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/nejm197210122871501</pub-id><pub-id pub-id-type="other">2-s2.0-0015504340</pub-id><pub-id pub-id-type="pmid">5056733</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandyk</surname><given-names>R.</given-names></name></person-group><article-title>The relationship between diabetes mellitus and Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">International Journal of Neuroscience</italic></source><year>1993</year><volume>69</volume><issue>1-4</issue><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.3109/00207459309003322</pub-id><pub-id pub-id-type="other">2-s2.0-0027561888</pub-id><pub-id pub-id-type="pmid">8082998</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorsey</surname><given-names>E. R.</given-names></name><name><surname>Constantinescu</surname><given-names>R.</given-names></name><name><surname>Thompson</surname><given-names>J. P.</given-names></name><etal/></person-group><article-title>Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030</article-title><source><italic toggle="yes">Neurology</italic></source><year>2006</year><volume>68</volume><issue>5</issue><fpage>384</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000247740.47667.03</pub-id><pub-id pub-id-type="other">2-s2.0-33846572874</pub-id><pub-id pub-id-type="pmid">17082464</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction</article-title><source><italic toggle="yes">European Review for Medical and Pharmacological Sciences</italic></source><year>2014</year><volume>18</volume><fpage>1790</fpage><lpage>1797</lpage><pub-id pub-id-type="pmid">24992623</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;n</surname><given-names>M. A.</given-names></name><name><surname>Takkouche</surname><given-names>B.</given-names></name><name><surname>Caama&#x000f1;o-Isorna</surname><given-names>F.</given-names></name><name><surname>Gestal-Otero</surname><given-names>J. J.</given-names></name></person-group><article-title>A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Annals of Neurology</italic></source><year>2002</year><volume>52</volume><issue>3</issue><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1002/ana.10277</pub-id><pub-id pub-id-type="other">2-s2.0-0036714747</pub-id><pub-id pub-id-type="pmid">12205639</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>J. A.</given-names></name><name><surname>Potashkin</surname><given-names>J. A.</given-names></name></person-group><article-title>System-based approaches to decode the molecular links in Parkinson&#x02019;s disease and diabetes</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2014</year><volume>72</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.03.019</pub-id><pub-id pub-id-type="other">2-s2.0-84909590793</pub-id><pub-id pub-id-type="pmid">24718034</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>Y.</given-names></name><name><surname>Galloway</surname><given-names>C. A.</given-names></name><name><surname>Jhun</surname><given-names>B. S.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name></person-group><article-title>Mitochondrial dynamics in diabetes</article-title><source><italic toggle="yes">Antioxidants &#x00026; Redox Signaling</italic></source><year>2011</year><volume>14</volume><issue>3</issue><fpage>439</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1089/ars.2010.3286</pub-id><pub-id pub-id-type="other">2-s2.0-78650856185</pub-id><pub-id pub-id-type="pmid">20518704</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karolina</surname><given-names>D. S.</given-names></name><name><surname>Armugam</surname><given-names>A.</given-names></name><name><surname>Tavintharan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2011</year><volume>6</volume><issue>8</issue><pub-id pub-id-type="publisher-id">e22839</pub-id><pub-id pub-id-type="doi">10.1371/annotation/698b7123-174f-4a09-95c9-fd6f5017d622</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potashkin</surname><given-names>J. A.</given-names></name><name><surname>Santiago</surname><given-names>J. A.</given-names></name><name><surname>Ravina</surname><given-names>B. M.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Leontovich</surname><given-names>A. A.</given-names></name></person-group><article-title>Biosignatures for Parkinson&#x02019;s disease and Atypical Parkinsonian disorders patients</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>8</issue><pub-id pub-id-type="publisher-id">e43595</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0043595</pub-id><pub-id pub-id-type="other">2-s2.0-84865420939</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulas</surname><given-names>J. A.</given-names></name><name><surname>Puig</surname><given-names>K. L.</given-names></name><name><surname>Combs</surname><given-names>C. K.</given-names></name></person-group><article-title>Amyloid precursor protein in pancreatic islets</article-title><source><italic toggle="yes">Journal of Endocrinology</italic></source><year>2017</year><volume>235</volume><issue>1</issue><fpage>49</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1530/joe-17-0122</pub-id><pub-id pub-id-type="other">2-s2.0-85029667651</pub-id><pub-id pub-id-type="pmid">28710249</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Harten</surname><given-names>B.</given-names></name><name><surname>de Leeuw</surname><given-names>F.-E.</given-names></name><name><surname>Weinstein</surname><given-names>H. C.</given-names></name><name><surname>Scheltens</surname><given-names>P.</given-names></name><name><surname>Biessels</surname><given-names>G. J.</given-names></name></person-group><article-title>Brain imaging in patients with diabetes: a systematic review</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2006</year><volume>29</volume><issue>11</issue><fpage>2539</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.2337/dc06-1637</pub-id><pub-id pub-id-type="other">2-s2.0-33845480120</pub-id><pub-id pub-id-type="pmid">17065699</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>P. T.</given-names></name><name><surname>Smith</surname><given-names>C. D.</given-names></name><name><surname>Abner</surname><given-names>E. A.</given-names></name><etal/></person-group><article-title>Human cerebral neuropathology of Type 2 diabetes mellitus</article-title><source><italic toggle="yes">Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</italic></source><year>2009</year><volume>1792</volume><issue>5</issue><fpage>454</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2008.08.005</pub-id><pub-id pub-id-type="other">2-s2.0-64549087258</pub-id><pub-id pub-id-type="pmid">18789386</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>C.</given-names></name><name><surname>Jick</surname><given-names>S. S.</given-names></name><name><surname>Meier</surname><given-names>C. R.</given-names></name></person-group><article-title>Risk of stroke in patients with idiopathic Parkinson disease</article-title><source><italic toggle="yes">Parkinsonism &#x00026; Related Disorders</italic></source><year>2010</year><volume>16</volume><issue>1</issue><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.06.005</pub-id><pub-id pub-id-type="other">2-s2.0-74149090924</pub-id><pub-id pub-id-type="pmid">19640771</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The serum lipid profile of Parkinson&#x02019;s disease patients: a study from China</article-title><source><italic toggle="yes">International Journal of Neuroscience</italic></source><year>2015</year><volume>125</volume><issue>11</issue><fpage>838</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.3109/00207454.2014.979288</pub-id><pub-id pub-id-type="other">2-s2.0-84942245856</pub-id><pub-id pub-id-type="pmid">25340257</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tansey</surname><given-names>M. G.</given-names></name></person-group><article-title>Neuroinflammation in Parkinson&#x02019;s disease: is there sufficient evidence for mechanism-based interventional therapy?</article-title><source><italic toggle="yes">Frontiers in Bioscience</italic></source><year>2008</year><volume>13</volume><issue>13</issue><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.2741/2713</pub-id><pub-id pub-id-type="other">2-s2.0-38449109568</pub-id><pub-id pub-id-type="pmid">17981581</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>P. A.</given-names></name><name><surname>Tetrud</surname><given-names>J. W.</given-names></name><name><surname>Langston</surname><given-names>J. W.</given-names></name></person-group><article-title>Permanent human parkinsonism due to 1-methy 1-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases</article-title><source><italic toggle="yes">Neurology</italic></source><year>1985</year><volume>35</volume><issue>7</issue><fpage>p. 949</fpage><pub-id pub-id-type="doi">10.1212/wnl.35.7.949</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>J.</given-names></name><name><surname>Ballard</surname><given-names>P.</given-names></name><name><surname>Tetrud</surname><given-names>J.</given-names></name><name><surname>Irwin</surname><given-names>I.</given-names></name></person-group><article-title>Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis</article-title><source><italic toggle="yes">Science</italic></source><year>1983</year><volume>219</volume><issue>4587</issue><fpage>979</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1126/science.6823561</pub-id><pub-id pub-id-type="pmid">6823561</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Przuntek</surname><given-names>H.</given-names></name><name><surname>Youdim</surname><given-names>M. B. H.</given-names></name></person-group><article-title>MPTP mechanisms of neurotoxicity and their implications for Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">European Journal of Pharmacology: Molecular Pharmacology</italic></source><year>1991</year><volume>208</volume><issue>4</issue><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/0922-4106(91)90073-q</pub-id><pub-id pub-id-type="other">2-s2.0-0025988085</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szendroedi</surname><given-names>J.</given-names></name><name><surname>Phielix</surname><given-names>E.</given-names></name><name><surname>Roden</surname><given-names>M.</given-names></name></person-group><article-title>The role of mitochondria in insulin resistance and type 2 diabetes mellitus</article-title><source><italic toggle="yes">Nature Reviews Endocrinology</italic></source><year>2011</year><volume>8</volume><issue>2</issue><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.138</pub-id><pub-id pub-id-type="other">2-s2.0-84856415487</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>M. H.</given-names></name><name><surname>Lavedan</surname><given-names>C.</given-names></name><name><surname>Leroy</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Mutation in the -synuclein gene identified in families with Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Science</italic></source><year>1997</year><volume>276</volume><issue>5321</issue><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id><pub-id pub-id-type="other">2-s2.0-0030744876</pub-id><pub-id pub-id-type="pmid">9197268</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebovitz</surname><given-names>H. I.</given-names></name></person-group><article-title>Insulin resistance: definition and consequences</article-title><source><italic toggle="yes">Experimental and Clinical Endocrinology &#x00026; Diabetes</italic></source><year>2001</year><volume>109</volume><issue>2</issue><fpage>135</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1055/s-2001-18576</pub-id><pub-id pub-id-type="other">2-s2.0-0034973768</pub-id><pub-id pub-id-type="pmid">11409294</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>D.</given-names></name><name><surname>Jain</surname><given-names>R.</given-names></name><name><surname>Eberhard</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes</article-title><source><italic toggle="yes">Journal of Molecular Cell Biology</italic></source><year>2012</year><volume>4</volume><issue>4</issue><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjs025</pub-id><pub-id pub-id-type="other">2-s2.0-84864829944</pub-id><pub-id pub-id-type="pmid">22611253</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Randell</surname><given-names>E.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Adeli</surname><given-names>K.</given-names></name><name><surname>Krahn</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>Q. H.</given-names></name></person-group><article-title>Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy</article-title><source><italic toggle="yes">Clinical Biochemistry</italic></source><year>2011</year><volume>44</volume><issue>4</issue><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2010.11.004</pub-id><pub-id pub-id-type="other">2-s2.0-79651470951</pub-id><pub-id pub-id-type="pmid">21126514</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains</article-title><source><italic toggle="yes">Journal of Neural Transmission</italic></source><year>2012</year><volume>119</volume><issue>4</issue><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1007/s00702-011-0724-4</pub-id><pub-id pub-id-type="other">2-s2.0-84863423974</pub-id><pub-id pub-id-type="pmid">22065205</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monte</surname><given-names>D. A. D.</given-names></name></person-group><article-title>The environment and Parkinson&#x02019;s disease: is the nigrostriatal system preferentially targeted by neurotoxins?</article-title><source><italic toggle="yes">The Lancet Neurology</italic></source><year>2003</year><volume>2</volume><issue>9</issue><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(03)00501-5</pub-id><pub-id pub-id-type="other">2-s2.0-0042521076</pub-id><pub-id pub-id-type="pmid">12941575</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicente Miranda</surname><given-names>H.</given-names></name><name><surname>El-Agnaf</surname><given-names>O. M. A.</given-names></name><name><surname>Outeiro</surname><given-names>T. F.</given-names></name></person-group><article-title>Glycation in Parkinson&#x02019;s disease and Alzheimer&#x02019;s disease</article-title><source><italic toggle="yes">Movement Disorders</italic></source><year>2016</year><volume>31</volume><issue>6</issue><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1002/mds.26566</pub-id><pub-id pub-id-type="other">2-s2.0-84959455993</pub-id><pub-id pub-id-type="pmid">26946341</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Metformin activates AMP-activated protein kinase by promoting formation of the <italic>&#x003b1;&#x003b2;&#x003b3;</italic> HETEROTRIMERIC COMPLEX</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2014</year><volume>290</volume><issue>6</issue><fpage>3793</fpage><lpage>3802</lpage><pub-id pub-id-type="doi">10.1074/jbc.m114.604421</pub-id><pub-id pub-id-type="other">2-s2.0-84922359822</pub-id><pub-id pub-id-type="pmid">25538235</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>C. J.</given-names></name><name><surname>Turner</surname><given-names>R. C.</given-names></name></person-group><article-title>Metformin</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>1996</year><volume>334</volume><issue>9</issue><fpage>574</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1056/nejm199602293340906</pub-id><pub-id pub-id-type="pmid">8569826</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Montalvo</surname><given-names>A.</given-names></name><name><surname>Mercken</surname><given-names>E.</given-names></name><name><surname>Mitchell</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Metformin improves healthspan and lifespan in mice</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2013</year><volume>4</volume><issue>1</issue><fpage>p. 2129</fpage><pub-id pub-id-type="doi">10.1038/ncomms3192</pub-id><pub-id pub-id-type="other">2-s2.0-84881347302</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Gallagher</surname><given-names>D.</given-names></name><name><surname>DeVito</surname><given-names>L. M.</given-names></name><etal/></person-group><article-title>Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation</article-title><source><italic toggle="yes">Cell Stem Cell</italic></source><year>2012</year><volume>11</volume><issue>1</issue><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.03.016</pub-id><pub-id pub-id-type="other">2-s2.0-84863614868</pub-id><pub-id pub-id-type="pmid">22770240</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulovic</surname><given-names>M.</given-names></name><name><surname>Jovanovic</surname><given-names>M.</given-names></name><name><surname>Xilouri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro</article-title><source><italic toggle="yes">Neurobiology of Disease</italic></source><year>2014</year><volume>63</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.11.002</pub-id><pub-id pub-id-type="other">2-s2.0-84890263516</pub-id><pub-id pub-id-type="pmid">24269733</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>F. M.</given-names></name><name><surname>Rorsman</surname><given-names>P.</given-names></name></person-group><article-title>KATP channels and islet hormone secretion: new insights and controversies</article-title><source><italic toggle="yes">Nature Reviews Endocrinology</italic></source><year>2013</year><volume>9</volume><issue>11</issue><fpage>660</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2013.166</pub-id><pub-id pub-id-type="other">2-s2.0-84886590372</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehlert</surname><given-names>D. R.</given-names></name><name><surname>Robertson</surname><given-names>D. W.</given-names></name></person-group><article-title>ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology</article-title><source><italic toggle="yes">Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>1994</year><volume>18</volume><issue>7</issue><fpage>1093</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1016/0278-5846(94)90113-9</pub-id><pub-id pub-id-type="other">2-s2.0-0027970799</pub-id><pub-id pub-id-type="pmid">7846282</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>L.-f.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>J.-h.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name></person-group><article-title>Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson&#x02019;s disease: Implications for treating Parkinson&#x02019;s disease?</article-title><source><italic toggle="yes">Neuropharmacology</italic></source><year>2005</year><volume>48</volume><issue>7</issue><fpage>984</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.01.009</pub-id><pub-id pub-id-type="other">2-s2.0-18044366947</pub-id><pub-id pub-id-type="pmid">15857625</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crestanello</surname><given-names>J. A.</given-names></name><name><surname>Doliba</surname><given-names>N. M.</given-names></name><name><surname>Babsky</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Opening of potassium channels protects mitochondrial function from calcium overload</article-title><source><italic toggle="yes">Journal of Surgical Research</italic></source><year>2000</year><volume>94</volume><issue>2</issue><fpage>116</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1006/jsre.2000.5979</pub-id><pub-id pub-id-type="other">2-s2.0-0033668709</pub-id><pub-id pub-id-type="pmid">11104651</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevener</surname><given-names>A. L.</given-names></name><name><surname>Olefsky</surname><given-names>J. M.</given-names></name><name><surname>Reichart</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Macrophage PPAR&#x003b3; is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>2007</year><volume>117</volume><issue>6</issue><fpage>1658</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1172/jci31561</pub-id><pub-id pub-id-type="other">2-s2.0-34249907880</pub-id><pub-id pub-id-type="pmid">17525798</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colca</surname><given-names>J. R.</given-names></name><name><surname>McDonald</surname><given-names>W. G.</given-names></name><name><surname>Waldon</surname><given-names>D. J.</given-names></name><etal/></person-group><article-title>Identification of a novel mitochondrial protein (&#x0201c;mitoNEET&#x0201d;) cross-linked specifically by a thiazolidinedione photoprobe</article-title><source><italic toggle="yes">American Journal of Physiology-Endocrinology and Metabolism</italic></source><year>2004</year><volume>286</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00424.2003</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paddock</surname><given-names>M. L.</given-names></name><name><surname>Wiley</surname><given-names>S. E.</given-names></name><name><surname>Axelrod</surname><given-names>H. L.</given-names></name><etal/></person-group><article-title>MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2007</year><volume>104</volume><issue>36</issue><fpage>14342</fpage><lpage>14347</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707189104</pub-id><pub-id pub-id-type="other">2-s2.0-35448995690</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>S. E.</given-names></name><name><surname>Paddock</surname><given-names>M. L.</given-names></name><name><surname>Abresch</surname><given-names>E. C.</given-names></name><etal/></person-group><article-title>The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2007</year><volume>282</volume><issue>33</issue><fpage>23745</fpage><lpage>23749</lpage><pub-id pub-id-type="doi">10.1074/jbc.c700107200</pub-id><pub-id pub-id-type="other">2-s2.0-34548254492</pub-id><pub-id pub-id-type="pmid">17584744</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Rahn</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells</article-title><source><italic toggle="yes">Molecular Pharmacology</italic></source><year>2007</year><volume>71</volume><issue>6</issue><fpage>1695</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1124/mol.106.033845</pub-id><pub-id pub-id-type="other">2-s2.0-34347346156</pub-id><pub-id pub-id-type="pmid">17387142</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pablo-Fern&#x000e1;ndez</surname><given-names>E.</given-names></name><name><surname>Breen</surname><given-names>D. P.</given-names></name><name><surname>Bouloux</surname><given-names>P. M.</given-names></name><name><surname>Barker</surname><given-names>R. A.</given-names></name><name><surname>Foltynie</surname><given-names>T.</given-names></name><name><surname>Warner</surname><given-names>T. T.</given-names></name></person-group><article-title>Neuroendocrine abnormalities in Parkinson&#x02019;s disease</article-title><source><italic toggle="yes">Journal of Neurology, Neurosurgery &#x00026; Psychiatry</italic></source><year>2016</year><volume>88</volume><issue>2</issue><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2016-314601</pub-id><pub-id pub-id-type="other">2-s2.0-84994884945</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;lscher</surname><given-names>C.</given-names></name></person-group><article-title>Drugs developed for treatment of diabetes show protective effects in Alzheimer&#x02019;s and Parkinson&#x02019;s diseases</article-title><source><italic toggle="yes">Sheng Li Xue Bao</italic></source><year>2014</year><volume>66</volume><fpage>497</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">25331995</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athauda</surname><given-names>D.</given-names></name><name><surname>Foltynie</surname><given-names>T.</given-names></name></person-group><article-title>Insulin resistance and Parkinson&#x02019;s disease: a new target for disease modification?</article-title><source><italic toggle="yes">Progress in Neurobiology</italic></source><year>2016</year><volume>145-146</volume><fpage>98</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2016.10.001</pub-id><pub-id pub-id-type="other">2-s2.0-84992383185</pub-id><pub-id pub-id-type="pmid">27713036</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athauda</surname><given-names>D.</given-names></name><name><surname>Wyse</surname><given-names>R.</given-names></name><name><surname>Brundin</surname><given-names>P.</given-names></name><name><surname>Foltynie</surname><given-names>T.</given-names></name></person-group><article-title>Is exenatide a treatment for Parkinson&#x02019;s disease?</article-title><source><italic toggle="yes">Journal of Parkinson&#x02019;s Disease</italic></source><year>2017</year><volume>7</volume><issue>3</issue><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.3233/jpd-171192</pub-id><pub-id pub-id-type="other">2-s2.0-85027417002</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efendic</surname><given-names>S.</given-names></name><name><surname>Portwood</surname><given-names>N.</given-names></name></person-group><article-title>Overview of incretin hormones</article-title><source><italic toggle="yes">Hormone and Metabolic Research</italic></source><year>2004</year><volume>36</volume><issue>11/12</issue><fpage>742</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1055/s-2004-826157</pub-id><pub-id pub-id-type="other">2-s2.0-12244311917</pub-id><pub-id pub-id-type="pmid">15655702</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matteucci</surname><given-names>E.</given-names></name><name><surname>Giampietro</surname><given-names>O.</given-names></name></person-group><article-title>Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors</article-title><source><italic toggle="yes">Current Medicinal Chemistry</italic></source><year>2015</year><volume>22</volume><issue>13</issue><fpage>1573</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.2174/0929867322666150227153308</pub-id><pub-id pub-id-type="other">2-s2.0-84931292010</pub-id><pub-id pub-id-type="pmid">25723507</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ericson</surname><given-names>L. E.</given-names></name><name><surname>H&#x000e5;kanson</surname><given-names>R.</given-names></name><name><surname>Lundquist</surname><given-names>I.</given-names></name></person-group><article-title>Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion</article-title><source><italic toggle="yes">Diabetologia</italic></source><year>1977</year><volume>13</volume><issue>2</issue><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1007/bf00745138</pub-id><pub-id pub-id-type="other">2-s2.0-0017578837</pub-id><pub-id pub-id-type="pmid">404204</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez Vicchi</surname><given-names>F.</given-names></name><name><surname>Luque</surname><given-names>G. M.</given-names></name><name><surname>Brie</surname><given-names>B.</given-names></name><name><surname>Nogueira</surname><given-names>J. P.</given-names></name><name><surname>Garcia Tornadu</surname><given-names>I.</given-names></name><name><surname>Becu-Villalobos</surname><given-names>D.</given-names></name></person-group><article-title>Dopaminergic drugs in type 2 diabetes and glucose homeostasis</article-title><source><italic toggle="yes">Pharmacological Research</italic></source><year>2016</year><volume>109</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2015.12.029</pub-id><pub-id pub-id-type="other">2-s2.0-84953439344</pub-id><pub-id pub-id-type="pmid">26748034</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Furigo</surname><given-names>I.</given-names></name></person-group><article-title>Estudo do mecanismo de a&#x000e7;&#x000e3;o da bromocriptina e de antagonistas de prolactina no tratamento do Diabetes Mellitus tipo 2 e da obesidade</article-title><year>2016</year><publisher-loc>S&#x000e3;o Paulo, Brazil</publisher-loc><publisher-name>Instituto de Ci&#x000ea;ncias Biom&#x000e9;dicas, Universidade de S&#x000e3;o Paulo</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.teses.usp.br/teses/disponiveis/42/42137/tde-16052017-145647/pt-br.php">http://www.teses.usp.br/teses/disponiveis/42/42137/tde-16052017-145647/pt-br.php</ext-link></comment></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of literature search to identify articles evaluating the relationship between T2DM and PD.</p></caption><graphic xlink:href="PD2019-4951379.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pathophysiological mechanism of PD that may favor the development of T2DM.</p></caption><graphic xlink:href="PD2019-4951379.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pathophysiological mechanism of T2DM that may favor the development of PD.</p></caption><graphic xlink:href="PD2019-4951379.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Relations of descriptors and studies found in PubMed database.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Descriptors</th><th align="center" rowspan="1" colspan="1">Number of articles</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Parkinson's disease&#x02009;&#x000d7;&#x02009;diabetes mellitus</td><td align="center" rowspan="1" colspan="1">335</td></tr><tr><td align="left" rowspan="1" colspan="1">Parkinson's disease&#x02009;&#x000d7;&#x02009;insulin resistance</td><td align="center" rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">Alpha-synuclein&#x02009;&#x000d7;&#x02009;diabetes mellitus</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">Alpha-synuclein&#x02009;&#x000d7;&#x02009;insulin resistance</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Islet amyloid polypeptide&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Metformin&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulfonylurea&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">Thiazolidinediones&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">GLP-1&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Bromocriptine&#x02009;&#x000d7;&#x02009;diabetes mellitus</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">Exenatide&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">Levodopa&#x02009;&#x000d7;&#x02009;diabetes mellitus</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="1" colspan="1">Dipeptidyl-peptidase IV inhibitors&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium-glucose transporter 2 inhibitors&#x02009;&#x000d7;&#x02009;Parkinson's disease</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Trials correlating PD and T2DM as a risk factor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Risk of PD in patients with T2DM</th><th align="center" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">Sample</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Increased (<italic>n</italic>&#x02009;=&#x02009;9)</td><td align="center" rowspan="1" colspan="1">De Pablo-Fernandez et al. [<xref rid="B20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 2,017,115<break/>Controls: 6,173,208</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">De Pablo-Fernandez et al. [<xref rid="B43" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 79 (14 with T2DM)<break/>Controls: 4.919 (842 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Yang et al. [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 36.294 (550 with PD)<break/>Controls: 108.882 (1232 with PD)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Yue et al. [<xref rid="B45" ref-type="bibr">45</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 6441<break/>Controls: 1.755.191</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Sun et al. [<xref rid="B46" ref-type="bibr">46</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 603.413 (1.613 with PD)<break/>Controls: 472.718 (809 with PD)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Wahlqvist et al. [<xref rid="B47" ref-type="bibr">47</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 64.166<break/>Controls: 698.587</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Schernhammer [<xref rid="B48" ref-type="bibr">48</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 1.931 (126 with T2DM)<break/>Controls: 9.651 (482 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Xu et al. [<xref rid="B49" ref-type="bibr">49</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 21.611 (172 with PD)<break/>Controls: 267.051 (1393 with PD)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Hu et al. [<xref rid="B19" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1">T2DM: 1.098 (24 with PD)<break/>Controls: 50.454 (609 with PD)</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Decreased (<italic>n</italic>&#x02009;=&#x02009;5)</td><td align="center" rowspan="1" colspan="1">Miyake et al. [<xref rid="B50" ref-type="bibr">50</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 249 (10 with T2DM)<break/>Controls: 368 (39 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">D&#x02032; Amelio et al. [<xref rid="B51" ref-type="bibr">51</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 318 (13 with T2DM)<break/>Controls: 318 (31 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Leibson et al. [<xref rid="B52" ref-type="bibr">52</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 197 (18 with T2DM)<break/>Controls: 197 (24 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Powers et al. [<xref rid="B53" ref-type="bibr">53</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 352 (26 with T2DM)<break/>Controls: 484 (61 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Herishanu et al. [<xref rid="B54" ref-type="bibr">54</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 93 (11 with T2DM)<break/>Controls: 93 (26 with T2DM)</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Not related (<italic>n</italic>&#x02009;=&#x02009;4)</td><td align="center" rowspan="1" colspan="1">Savica et al. [<xref rid="B22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 196 (13 with T2DM)<break/>Controls: 196 (17 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Palacios et al. [<xref rid="B55" ref-type="bibr">55</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 656<break/>Controls: 147,440</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Driver et al. [<xref rid="B56" ref-type="bibr">56</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 556<break/>Controls: 21.285</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Simon et al. [<xref rid="B57" ref-type="bibr">57</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 530 (37 with T2DM)<break/>Controls: 171.349 (3.722 with T2DM)</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Risk of T2DM in patients with PD</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Decreased (<italic>n</italic>&#x02009;=&#x02009;2)</td><td align="center" rowspan="1" colspan="1">Becker et al. [<xref rid="B58" ref-type="bibr">58</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 3.637 (291 with T2DM)<break/>Controls: 3.637 (308 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Scigliano et al. [<xref rid="B59" ref-type="bibr">59</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 178 (6 with T2DM)<break/>Controls: 534 (58 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased (<italic>n</italic>&#x02009;=&#x02009;1)</td><td align="center" rowspan="1" colspan="1">Pressley et al. [<xref rid="B60" ref-type="bibr">60</xref>]</td><td align="center" rowspan="1" colspan="1">PD: 791 (235 with T2DM)<break/>Controls: 24.040 (5.175 with T2DM)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total&#x02009;=&#x02009;21</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Trials correlating genetic profile and T2DM/PD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">Sample (controls/PD/T2DM)</th><th align="center" rowspan="1" colspan="1">Correlation between T2DM and PD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Chung et al. [<xref rid="B61" ref-type="bibr">61</xref>]</td><td align="center" rowspan="1" colspan="1">500/500/102</td><td align="center" rowspan="1" colspan="1">No correlation</td></tr><tr><td align="left" rowspan="1" colspan="1">Santiago et al. [<xref rid="B62" ref-type="bibr">62</xref>]</td><td align="center" rowspan="1" colspan="1">46/50/10</td><td align="center" rowspan="1" colspan="1">84 genes</td></tr><tr><td align="left" rowspan="1" colspan="1">Santiago et al. [<xref rid="B63" ref-type="bibr">63</xref>]</td><td align="center" rowspan="1" colspan="1">91/101/11</td><td align="center" rowspan="1" colspan="1">478 genes<break/>7 genes (microarray)</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Trials correlating clinical features of patients with PD and T2DM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Influence of T2DM on PD</th><th align="center" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">PD with T2DM/PD without T2DM</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Major cognitive impairment (<italic>n</italic>&#x02009;=&#x02009;3)</td><td align="center" rowspan="1" colspan="1">Ong et al. [<xref rid="B65" ref-type="bibr">65</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 11<break/>PD without T2DM: 51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Petrou et al. [<xref rid="B66" ref-type="bibr">66</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 12<break/>PD without T2DM: 24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Bohnen et al. [<xref rid="B67" ref-type="bibr">67</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 15<break/>PD without T2DM: 133</td></tr><tr><td align="left" colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Worsening of motor symptoms and/or postural instability (<italic>n</italic>&#x02009;=&#x02009;4)</td><td align="center" rowspan="1" colspan="1">Mohamed Ibrahim et al. [<xref rid="B68" ref-type="bibr">68</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 25<break/>PD without T2DM: 25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Pagano et al. [<xref rid="B69" ref-type="bibr">69</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 21<break/>PD without T2DM: 51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Kotagal et al. [<xref rid="B70" ref-type="bibr">70</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 13<break/>PD without T2DM: 26</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Cereda et al. [<xref rid="B71" ref-type="bibr">71</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 466<break/>PD without T2DM: 921</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Influence of PD on T2DM</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Reduction of glycemia and/or glycated hemoglobin and lipid profile improvement (<italic>n</italic>&#x02009;=&#x02009;1)</td><td align="center" rowspan="1" colspan="1">Scheuing et al. [<xref rid="B72" ref-type="bibr">72</xref>]</td><td align="center" rowspan="1" colspan="1">PD with T2DM: 1579<break/>PD without T2DM: 177.413</td></tr></tbody></table></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Protection of anti-Parkinson's drugs in T2DM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">LEVODOPA</th><th align="center" rowspan="1" colspan="1">BROMOCRPTINE</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Human trials</bold>: Cereda et al. [<xref rid="B71" ref-type="bibr">71</xref>], Rosati et al. [<xref rid="B73" ref-type="bibr">73</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials</bold> Chamarthi et al. [<xref rid="B74" ref-type="bibr">74</xref>]<break/>Roe et al. [<xref rid="B75" ref-type="bibr">75</xref>], Ghosh et al. [<xref rid="B76" ref-type="bibr">76</xref>], Gaziano et al. [<xref rid="B77" ref-type="bibr">77</xref>], Vinik et al. [<xref rid="B78" ref-type="bibr">78</xref>], Pijl et al. [<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">
<bold>Animal studies:</bold> Ezrokhi et al. [<xref rid="B80" ref-type="bibr">80</xref>], Luo et al. [<xref rid="B81" ref-type="bibr">81</xref>], Luo et al. [<xref rid="B82" ref-type="bibr">82</xref>], Cincotta et al. [<xref rid="B83" ref-type="bibr">83</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Protection of antidiabetic drugs in PD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3" rowspan="1">METFORMIN</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Katila et al. [<xref rid="B25" ref-type="bibr">25</xref>], Ryu et al. [<xref rid="B84" ref-type="bibr">84</xref>], Ismael et al. [<xref rid="B85" ref-type="bibr">85</xref>], Patil et al. [<xref rid="B86" ref-type="bibr">86</xref>], Choi et al. [<xref rid="B87" ref-type="bibr">87</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials</bold>: Kuan et al. [<xref rid="B88" ref-type="bibr">88</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Cell culture studies</bold>: Fitzgerald et al. [<xref rid="B89" ref-type="bibr">89</xref>]</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">GLP-1 Agonist (Exenatide/Liraglutide/Semaglutide<bold>)</bold></td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Zhang et al. [<xref rid="B90" ref-type="bibr">90</xref>], Bassil et al. [<xref rid="B27" ref-type="bibr">27</xref>], Cao et al. [<xref rid="B91" ref-type="bibr">91</xref>], Hansen et al. [<xref rid="B92" ref-type="bibr">92</xref>], Kim et al. [<xref rid="B93" ref-type="bibr">93</xref>], Li et al. [<xref rid="B94" ref-type="bibr">94</xref>], Bertilsson et al. [<xref rid="B95" ref-type="bibr">95</xref>], Harkavyi et al. [<xref rid="B96" ref-type="bibr">96</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials</bold>: Athauda et al. [<xref rid="B97" ref-type="bibr">97</xref>], Bassil et al. [<xref rid="B90" ref-type="bibr">90</xref>], Aviles-Olmos et al. [<xref rid="B98" ref-type="bibr">98</xref>], Aviles-Olmos et al. [<xref rid="B99" ref-type="bibr">99</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Cell culture studies</bold>: Jalewa et al. [<xref rid="B100" ref-type="bibr">100</xref>], Perry et al. [<xref rid="B101" ref-type="bibr">101</xref>]</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">GIP Agonist (D-Ala2-GIP-glu-PAL)</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="2" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Feng et al. [<xref rid="B102" ref-type="bibr">102</xref>], Li et al. [<xref rid="B103" ref-type="bibr">103</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Cell culture studies</bold>: Jalewa et al. [<xref rid="B100" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">DPP-4 Inhibitors</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="2" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Abdelsalam et al. [<xref rid="B104" ref-type="bibr">104</xref>], Pipatpiboon et al. [<xref rid="B105" ref-type="bibr">105</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials:</bold> Svenningsson et al. [<xref rid="B106" ref-type="bibr">106</xref>]</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulphonylurea</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>No</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Obata et al. [<xref rid="B26" ref-type="bibr">26</xref>], Kou et al. [<xref rid="B107" ref-type="bibr">107</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials</bold>: Wahlqvist et al. [<xref rid="B47" ref-type="bibr">47</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Cell culture studies</bold>: Tai et al. [<xref rid="B108" ref-type="bibr">108</xref>]</td></tr><tr><td colspan="3" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Thiazolidinediones</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>No consensus</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Yes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Animal studies</bold>: Pinto et al. [<xref rid="B28" ref-type="bibr">28</xref>], Martinez et al. [<xref rid="B109" ref-type="bibr">109</xref>] Ren et al. [<xref rid="B110" ref-type="bibr">110</xref>], Barbiero et al. [<xref rid="B111" ref-type="bibr">111</xref>], Pisanu et al. [<xref rid="B112" ref-type="bibr">112</xref>], Quinn et al. [<xref rid="B113" ref-type="bibr">113</xref>], Hunter et al. [<xref rid="B114" ref-type="bibr">114</xref>], Dehmer et al. [<xref rid="B115" ref-type="bibr">115</xref>], Breidert et al. [<xref rid="B116" ref-type="bibr">116</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Human trials</bold>: Brakedal et al. [<xref rid="B117" ref-type="bibr">117</xref>], Brauer et al. [<xref rid="B118" ref-type="bibr">118</xref>], Ninds Exploratory trials in Parkinson's disease FS-ZONE, Investigators et al. [<xref rid="B119" ref-type="bibr">119</xref>], Simon et al. [<xref rid="B120" ref-type="bibr">120</xref>]</td><td align="center" rowspan="1" colspan="1">
<bold>Cell culture studies</bold>: Jung et al. [<xref rid="B121" ref-type="bibr">121</xref>], Xing et al. [<xref rid="B122" ref-type="bibr">122</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>